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PROTECTIVE ACTION OF NERVE GROWTH FACTOR (NGF) ON DEGENERATING 
RETINAL CELLS: NGF MEDIATES THE RESCUE EFFECT OF ADYPOCYTES?
Luigi Aloe and Maria-Luisa Rocco
Institute of Cell Biology and Neurobiology, CNR, Rome, Italy
Nerve growth factor (NGF) is endogenous biological mol-
ecules produced and released but numerous neuronal and 
non-neuronal cells including adipocytes, we have recently re-
ported1. We have also demonstrated that topical puried NGF 
administration on eyes exerts a protective action on degener-
ating retinal cells in glaucoma, maculopathy, diabetic retin-
opathy, and retinitis pigmentosa. Interestingly, there is indi-
cating that intravitreal transplantation of adipose stem cells 
exerts protective action on retinal ganglion cells via secreted 
growth factors2 and also in animal models of glaucoma3 and in 
diabetic retinopathy4. Likewise, mesenchyme stem cells can be 
potential useful to rescue retinal degeneration5. Despite these 
evidences, mechanism through which adipocytes can actually 
secrete NGF in situ and lead to long-term benets in the ab-
sence of undesired side e!ects is not full clear. "e aim of the 
present presentation is to reveal ndings regarding our data 
on the role of NGF on retinal cells and photoreceptors and 
discuss the hypothesis as to whether adipocytes present in the 
visual tissue might release NGF and be involved in the protec-
tive action on damaged retinal cells.
1.  Sornelli F, Fiore M, Chaldakov GN, Aloe L. Adipose tis-
sue-derived nerve growth factor and brain-derived neuro-
trophic factor: results from experimental stress and diabe-
tes. Gen Physiol Biophys. 2009.
2.  Sugitani S, Tsuruma K, Ohno Y, Kuse Y, Yamauchi M, Ega-
shira Y, Yoshimura S, Shimazawa M, Iwama T, Hara H. "e 
potential neuroprotective e!ect of human adipose stem 
cells conditioned medium against light-induced retinal 
damage. Exp Eye Res. 2013.
3.  Emre E, Yüksel N, Duruksu G, Pirhan D, Subaşi C, Erman 
G, Karaöz E. Neuroprotective e!ects of intravitreally trans-
planted adipose tissue and bone marrow-derived mesen-
chymal stem cells in an experimental ocular hypertension 
model. Cytotherapy. 2015.
4.  Rajashekhar G, Ramadan A, Abburi C, Callaghan B, Traktuev 
DO, Evans-Molina C, Maturi R, Harris A, Kern TS, March KL. 
Regenerative therapeutic potential of adipose stromal cells in 
early stage diabetic retinopathy. PLoS One. 2014.
5.  Harasymiak-Krzyżanowska I, Niedojadło A, Karwat J, 
Kotuła L, Gil-Kulik P, Sawiuk M, Kocki J. Adipose tissue-
derived stem cells show considerable promise for regenera-
tive medicine applications. Cell Mol Biol Lett. 2013
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ADIPOKINES IN METABOLIC SYNDROME
Pepa Atanassova1, Petar Hrischev2, Katerina Georgieva2 , Penka Angelova2, Nikolay Boydziev2, 
Dora Terzieva3
1Department of Anatomy, Histology and Embryology, 2Department of Physiology, 3Clinical Laboratory;  
Medical University, Plovdiv, Bulgaria
e metabolic syndrome (MetSyn) is one of the pressing 
problems of civilization, which is caused by variety of clinical 
manifestations and lack of uniform criteria for diagnosis. It is 
a complex of metabolic disorders, which is based on obesity, 
dyslipidemia, insulin resistance, compensatory hyperinsuline-
mia, hypertention. Areas of active investigation focus on its 
molecular bases and potential pathogenic role of metabolic 
inammation. A body of evidence suggests the presence of an 
overall, low-grade inammation in obesity and MetSyn, with 
altered levels of several circulating factors such as an increase 
in the plasma levels of C-reactive protein, tumor necrosis 
factor-α, interleukin-6, transforming growth factor-beta and 
other biological markers of inammation. We throw a light 
upon this question by studying the expression of some adipo-
kenes - leptin, NGF and adiponectin in women with MetSyn 
and rats with MetSyn induced by high-fat-carbohydrate diet 
(HFCD). 
Sixty premenopausal women with MetSyn and 60-age-
matched clinically healthy women (age range 30-45 years) were 
included in the study. HFSD was applied in 20 male Wistar 
rats to induce obesity and MetSyn. Other 20 male rats which 
received standard rat chow were used as controls. Plasma 
leptin, NGF and adiponectin levels were measured by means 
of a solid-phase immunoenzyme assay (ELISA) performed 
according to the manufacturer’s instructions (Human leptin 
ELISA, Human adiponectin (HEK) ELISA, Human NGF 
ELISA, BioVendor Laboratory, Medicin, Inc., Czech Republic). 
Immunohistochemical demonstration of leptin and NGF was 
carried out by the avidin-biotin peroxidase (ABC) method  in 
subcutaneous white adipose tissue of the gluteal region.
e diagnosis metabolic syndrome was given aer measur-
ing the waist circumference, body mass index, glucose, insulin, 
total cholesterol and triglycerides plasma levels for each subject. 
e immunochemical results showed plasma levels of leptin 
and NGF of the women with MetSyn over-expressed (P<0.01). 
ey correlated with body mass index, waist circumference, 
lipid prole and insulinemia in the subjects with MetSyn. Adi-
ponectin levels were inversely associated with Met Syn. e ap-
plication of HFSD induced MetSyn in the rats, which resulted 
in increased leptin and NGF plasma levels as compared with 
the control group (P<0.05). Unlike the women with MetSyn, in 
rat MetSyn the serum adiponectin levels were not signicantly 
dierent than that of the controls. e immunohistochemical 
expressions in subcutaneous adipose tissue corresponded im-
munochemical data. e leptin and NGF reactions in Met Syn 
was stronger (+++) than that of the control group (+). 
e application of HFSD in rats is a good experimental 
model for inducement of metabolic syndrome. It successfully 
imitates the pathology in humans. Our results suggest the 
possible role of the adipokines: leptin, NGF and adiponectin 




HYDROGEN SULFIDE MEDIATES ENHANCED LIPOLYSIS IN VISCERAL ADIPOSE 
TISSUE OF OBESE RATS
Jerzy Bełtowski1*, Grażyna Wójcicka1, Marta Rusek1, Anna Jamroz-Wisniewska2
1Department of Pathophysiology, Medical University, Lublin, Poland
2Department of Neurology, Medical University, Lublin, Poland
*Correspondence: jerzy.beltowski@umlub.pl
Lipolysis is the principal metabolic function of the adipose 
tissue. Obese animals and humans are characterized by en-
hanced baseline lipolysis especially in visceral adipose tissue. 
Excessive release of non-esteried fatty acids contributes to 
insulin resistance and lipotoxicity in remote tissues. We exam-
ined the role of H
2
S, the endogenous “gasotransmitter”, in the 
regulation of AT lipolysis.
Microdialysis probe was inserted into the mesenteric fat 
depot of anesthetized rats and was perfused with Ringer’s so-
lution at the rate of 1 μl/min. Fractions were collected in 10-
min intervals and the rate of lipolysis was assessed by measur-





S, increased glycerol release in a concentra-
tion-dependent manner. In addition, Na
2
S increased cAMP 
production and its lipolytic eect  was abolished by protein 
kinase A inhibitor, KT5720. Glycerol release was signicantly 
higher in mesenteric AT of rats made obese by feeding highly 
palatable diet for 1 month. H
2
S concentration in the dialysate 
was by 168% higher in obese animals. Propargylglycine, the 
inhibitor of H
2
S-synthesizing enzyme, cystathionine γ-laye 
(CSE), reduced lipolysis in lean and obese rats and abolished 
the dierence in glycerol release between these two groups. 
Next, we examined why H
2
S is higher in AT of obese rats. H
2
S 
is synthesized from L-cysteine by CSE and is enzymatically 
oxidized in mitochondria. CSE expression and activity were 
similar in lean and obese rats. In addition, H
2
S production by 
adipose tissue explants measured in the presence of stigmatel-
lin, the inhibitor of mitochondrial H
2
S oxidation, did not dif-
fer between groups. However, mitochondrial H
2
S oxidation, 
measured as the dierence in H
2
S production in the presence 
and in the absence of stigmatellin, was markedly reduced in 
obese rats. Finally, we looked at several factors which deter-
mine the rate of mitochondrial H
2
S oxidation. First, mito-
chondria density, measured as the expression of cytochrome 
C and citrate synthase activity, was similar in lean and obese 
rats. Second, the activity of sulde:quinone oxidoreductase 
(SQR), the rate-limiting enzyme in mitochondrial H
2
S oxi-
dation, as well as the concentration of ubiquinone (the SQR 
cofactor) did not dier as well. However, oxygen tension was 
3-fold lower in mesenteric AT of obese rats. Finally, H
2
S pro-
duction by AT explants incubated at 5% O
2
 was higher in 
obese than in lean rats, however, increasing O
2
 concentration 
to 21% markedly reduced H
2
S production and abolished the 
dierence between both groups.
(i) Exo- and endogenous H
2
S stimulates lipolysis in vis-
ceral adipose tissue in cAMP-protein kinase A dependent 
manner, (ii) H
2
S production in visceral adipose tissue in-
creases in obesity, and H
2
S drives enhanced lipolysis rate, 
(iii) enhanced H
2
S production in AT of obese rats does not 
result from increased synthesis but rather from reduced mi-
tochondrial oxidation due to adipose tissue hypoxia. e 
results indicate that adipose tissue hypoxia, by enhancing 
net H
2
S production, plays a key role in hyperlipolytic state 
associated with obesity and thus may contribute to compli-
cations such as insulin resistance and lipotoxicity. Inhibiting 
H
2
S system may be a novel treatment strategy to combat det-
rimental metabolic consequences associated with the meta-
bolic syndrome.
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CHARACTERISTICS OF THE ALCOHOLIC PATIENTS WITH HYPOGLYCAEMIA
Chiara Boccardo1, Andrea Zizzo1, Enrico Baldini1, Gemma Battagliese2, Ida Capriglione2,  
Claudia Rotondo2
1UOC Medicina D‘Urgenza,  Sapienza Università di Roma, Italy
2Centro di Riferimento Alcologico, Sapienza Università di Roma, Italy
Several studies have shown that alcohol abuse can lead to hy-
poglycaemia. Although it is not known to what extent, this 
correlation is well explained in terms of pathophysiology. For 
this purpose we observed a population of alcoholic patients 
suering from hypoglycaemia. We conducted a retrospective 
study in the Emergency Department of Policlinico Umberto I 
in Rome, analyzing all the entrances and all the patients coming 
with hypoglycaemia from January 2012 to December 2013. We 
assessed the patients with blood glucose levels less than 70 mg/
dl. In so doing, we recruited 441 patients identied as the target 
population, and we also selected a group of 52 patients show-
ing hypoglycaemia associated with acute alcohol intoxication or 
chronic alcoholism. Comparing the group of alcoholics and the 
main population, it turned out that there was a predominance 
of male sex, and a lower average age among alcoholics with 
hypoglycaemia with regard to the entire hypoglycaemic popu-
lation Moreover in the group of alcoholics there was a higher 
incidence of consciousness alterations, whereas average blood 
glucose levels and the presence of hepatic impairment show no 
dierence between the two groups.
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OBESITY RELATED ALTERATIONS IN DRUG DISPOSITION AND 
PHARMACOKINETICS: EMERGING CLINICAL IMPLICATIONS IN OBESE PATIENTS 
Harpal S. Buttar  and Natasha Chander
Department of Pathology and Laboratory Medicine, School of Medicine, University of Ottawa, Ontario, 
Canada and University of Guelph, Ontario, Canada 
Correspondence: drharpalbuttar@gmail.com
Obesity is characterized by the abnormal or excessive accu-
mulation of body fat with a body mass index (BMI) ≥ 30.0 kg/
m2, whereas the BMI of non-obese individuals ranges from 
18.5-24.9 kg/m2. is non-communicable but chronic disor-
der contributes heavily to major risk factors involved in the 
occurrence of type 2 diabetes, osteoarthritis, cancer, and car-
diovascular and neuropsychiatric diseases, all of which can 
potentially lead to severe morbidity and mortality. Extreme 
obesity (BMI 35-40 kg/m2) also causes stress on the respira-
tory system, decreasing the individual’s functional residual 
capacity. Obesity-induced cardio-respiratory stress interferes 
with the cardiovascular system by demanding an increased 
circulating blood volume, and consequently subjecting the 
le ventricle to both pressure and volume overload. ese fac-
tors subsequently change drug’s pharmacokinetics (PK) and 
disposition in obese patients.  Many co-morbid conditions 
associated with obesity require polypharmaceutical interven-
tions.  Administration of dierent types of drugs may not only 
cause adverse drug-drug interactions but may also produce 
changes in PK and pharmacodynamics (PD) of drugs, espe-
cially lipid soluble agents. Dierences in volume of distribu-
tion or clearance that result from excess adipose tissue can 
lead to improper dosing, oen leaving patients mistreated for 
their ailments. Obesity related changes in metabolism, distri-
bution, PK and PD parameters of lipid soluble drugs may pro-
foundly alter in obese patients, thereby requiring drug dose 
adjustment. Adipose tissue contains CYP17 and CYP19 and 
is capable of producing sex steroid hormones like the testes 
and ovary (1). e sex steroid hormones originating from adi-
pose tissue may cause induction/inhibition of major drug me-





consequently modify drug metabolism/disposition in obese 
subjects. It has been reported that xenobiotic-metabolizing 
CYP
450s
 are also expressed in the adipose tissue, especially 
CYP1A1 and CYP1B1 that can bioactivate carcinogenic poly-
cyclic aromatic hydrocarbons and exogenous estrogens (2). In 
view of all these factors, inclusion of obese men and women in 
clinical trials is needed for better understanding the distribu-
tion, biodegradation, PK and PD proles of old and new drugs 
in obese patients.
With the increasing population of overweight and obese peo-
ple in today’s obesogenic society, it is vital that dosing regimens 
for antimicrobials, anticancer agents, anesthetics, analgesics, 
oral contraceptives, and antipsychotics are also formulated for 
obese subjects and not only for lean individuals. It is no longer 
sucient to base drug doses on size metrics such as body weight 
alone. is communication will provide an updated overview 
about the metabolic disposition, PK and PD changes of a wide 
spectrum of drugs in obese and non-obese patients. 
1. Kinoshita T, Honma S, Shibata Y, et al. An innovative LC-
MS/MS-based  method for determining CYP17 and CYP19 
activity in the adipose tissue of pre- and post-menopausal 
and ovariectomized women using 13C-labelled steroid sub-
strates. J Clin Endocrinol Metab 2014; 99: 1339-1347.
2. Yanev S, Chaldakov GN. Adipotoxicology of obesity and 
related diseases. Biomed  Rev 2012; 23: 53-60.
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RESISTIN/ADIPONECTIN/FGF21 INTERACTIONS IN T2DM RODENT MODELS 
Arieh Gertler
The Institute of Biochemistry, Food Science, and Nutrition, The Hebrew University of Jerusalem, Rehovot, Israel
Obesity and type2 diabetes share several features such as in-
sulin resistance and energy homeostasis deregulation driven 
by changes of adipose tissue secreted hormones.  Indeed, 
adiponectin, an insulin-sensitizing hormone, and resistin, 
known to promote insulin resistance, are potential links 
between obesity and type2 diabetes. In addition, Fibroblast 
growth factor 21 (FGF21), predominantly produced by the 
liver, has similar eects as adiponectin in regulating glucose/
lipid metabolism and insulin sensitivity. However, the in-
terplay between adiponectin, FGF21 and resistin signaling 
pathways in the onset of insulin resistance is unknown. In 
the present study, we (1) investigated whether central resis-
tin promotes insulin resistance through the impairment of 
adiponectin signalling and by promoting FGF21 resistance 
and (2) whether we can block resistin action using resistin 
mutant acting as resistin antagonist.
Chronic ICV resistin infusion down regulated both hypo-
thalamic and hepatic APPL1, a key protein in adiponectin sig-
nalling, associated with decreased Akt/APPL1 interaction and 
an increased Akt association with its endogenous inhibitor 
TRB3.  Resistin treatment also reduced the expression of adi-
ponectin receptors in hypothalamus, liver, muscle and adipose 
tissue. Furthermore central resistin acting through TLR4 im-
paired insulin sensitivity consequently to the downregulation 
of FGF21 and its receptor components in the hypothalamus 
and peripheral tissues promoting FGF21 resistance. We also 
showed that resistin eects are abolished in TLR4 knock-out 
mice and in cells expressing TLR4 siRNAs. 
To block resistin action in mice fed high fat diet (HFD) 
that are prone to obesity and inammation, and in attempt 
to reverse these metabolic disorders we have developed and 
puried to homogeneity recombinant human resistin mutant 
that acts as resistin antagonist (RA). We tested the ecacy of 
RA in human neuroblastoma cell line SH-SY5Y and in mouse 
hypothalamic cell line mHypo 280. First, we showed that re-
sistin- induced the phosphorylation of Akt could be blocked 
completely and in lower doses gradually abolished. Once, the 
ecacy of RA in vitro was demonstrated, we attempted to re-
verse the HFD-dependent insulin resistance by RA treatment 
in vivo. For this purpose, we have fed male C57BL/6 mice with 
HFD for 6 weeks and then mice received for 14 days daily in-
jection of RA (0.3 mg/day/mice), while a control group was 
that received chow diet was treated similarly. We show that 
RA led to a signicant decrease in body weight of HFD mice 
mainly due to loss of visceral fat and  restored glucose toler-
ance and insulin-responsiveness as evidenced respectively by 
glucose tolerance test and by insulin tolerance test. In con-
clusion, we demonstrated that the blockade of resistin action 
reduced body weight gain, visceral fat content and restored 
insulin responsiveness of mice fed HFD.
In summary, our study reveals novel mechanism explaining 
the onset of insulin resistance orchestrated by central resistin/




ADIPOBIOLOGY: A RESEARCH FIELD MARKED BY FIVE PARADIGM SHIFTS
George N. Chaldakov1, Luigi Aloe2, Anton B. Tonchev1, Marco Fiore2, Plamen Panayotov3,  
Gorana Ranćić4, Neşe Tunçel5, Jerzy Beltowski6, Stoyan Stoev7, Marin Zhelezov1,  
Peter I. Ghenev8, Alexander Hinev9, Nikolay Evtimov10, Stanislav Yanev11
1Laboratory of Cell Biology, Department of Anatomy and Histology, Medical University, Varna, Bulgaria, 
2Institute of Cell Biology and Neurobiology, CNR, Rome, Italy, 3Department of Cardiac Surgery,  
St Marina University Hospital, Varna, Bulgaria, 4Department of Histology, Medical Faculty, Niš, Serbia, 
5Department of Physiology, Medical Faculty, Osmangazi University, Eskişehir, Turkey,  
6Department of Pathophysiology, Medical University, Lublin, Poland, 7Department of Forensic Medicine, 
Medical University, So#a, Bulgaria, 8Department of Pathology, Medical University, Varna, Bulgaria,  
9Urology Clinic, St Marina University Hospital, Varna, Bulgaria, 10Urology Clinic, St Anna University Hospital, 
Varna, Bulgaria, 11Laboratory of Drug Toxicology, Institute of Neurobiology, BAS, So#a, Bulgaria 
Correspondence: chaldakov@yahoo.com
In this candlelight lecture we will start with a brief histori-
cal survey. Admittedly, the accumulation of adipose tissue 
(AT) was linked to obesity. This was known to Hippocrates, 
who stated that “sudden death is more common in those 
who are naturally fat than in the lean”. omas Short’s book, 
A Discourse Concerning the Causes and Eects of Corpulency 
(1727), was the first English language monograph on obesity. 
e adipocyte, !rstly dubbed “fat vesicle”,  was recognized as 
a speci!c cell type of AT by Hassall (1849). Recently, AT has 
taken a center stage in many diverse diseases beyond obesity. 
Based on this intellectual growth process a new !eld of re-
search, adipobiology, was conceptualized (1). Since the discov-
ery of leptin (1994), AT has undergone !ve major paradigm 
shi"s (in sense of omas Kuhn). e !rst paradigm shi": 
from merely a fat storage, AT is now known as a major en-
docrine and paracrine organ of the human body, produc-
ing more than 200 signaling proteins (adipokines) (2). e 
second paradigm shi": external versus internal adipose depot 
that spotlights our knowledge about TOFI (thin outside, fat 
inside) and related phenotypes (3). e third paradigm shi": 
white versus brown adipocytes, recovering the signi!cance of 
brown adipobiology (4). e fourth paradigm shi": a link be-
tween AT and the human exposome, that is, adipotoxicology 
(5). e !"h paradigm shi": the involvement of adipokines 
in the pathogenesis of psychiatric (6) and neurodegenerative 
diseases, including adipose-Alzheimer (7). 
1.  Chaldakov GN, Stankulov IS, Hristova MG, Ghenev 
PI. Adipobiology of disease: adipokines and adipokine-
targeted pharmacology. Curr Pharm Des 2003; 9: 1023-
1031. 
2.  Renes J, Mariman E. Application of proteomics technology 
in adipocyte biology. Mol Biosyst 2013; 9: 1076-1091.
3.  Ranćić G, Petrovic A, Sekulovic-Stefanovic L, Bojamic 
V, Ghenev PI. Adipotopogrpahy: TOFI versus TOTI, or 
a hidden Homo obesus [Abstract]. In: 1st ISAA, Varna, 
Bulgaria, 20 October 2007. pp 13-14.
4.  Sacks H, Symonds ME. Anatomical locations of human 
brown adipose tissue: functional relevance and implications 
in obesity and type 2 diabetes. Diabetes 2013; 62: 1783-1790. 
5.  Chaldakov GN, Yanev S, Georgiev V. Toxicology of adipose 
tissue (adipotoxicology) or adipose tissue as a “toxicrine” 
organ. In: G.N. Pierce et al, editors. Advanced Bioactive 
Compounds Countering the Eects of Radiological, Chemical 
and Biological Agents. Chapter 22.  pp 253-260. NATO 
Science for Peace and Security Series A: Chemistry and 
Biology, Springer Science+Business Media Dordrecht 2013. 
6.  Wędrychowicz A, Zając A, Pilecki M, Kościelniak B, 
Tomasik PJ. Peptides from adipose tissue in mental 
disorders. World J Psychiatr 2014; 4: 103-111.
7.  Ranćić G, Fiore M, Pancheva R, Tunçel N, Beltowski J, 
Zhelezov M, et al.  Adipose tissue: the Renaissance marked 
by four paradigm shi"s.  Adipobiology 2014; 6: 49-53.
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UNRAVELING THE OXIDATIVE POTENTIAL OF EPICARDIAL FAT IN HUMANS
Kanta Chechi, Pierre Voisine, Patrick Mathieu and Denis Richard 
Quebec Heart Lung Institute, Universite Laval, Quebec, Canada
Epicardial adipose tissue is a unique fat depot around the 
heart that shares a close anatomic proximity and vascular 
supply with the myocardium and coronary arteries. Its accu-
mulation around the heart, measured using various imaging 
modalities, has been associated with the onset and progres-
sion of coronary artery disease in humans. We, and others, 
have reported that human epicardial adipose tissue expresses 
uncoupling protein 1 (UCP1), a marker of brown adipocytes, 
at both mRNA and protein levels. Presence of UCP1 was also 
associated with a higher capacity for oxidizing fatty acids in 
epicardial fat relative to subcutaneous fat in our cohort. In ad-
dition, expression levels of most genes involved in thermo-
genesis including UCP1 exhibited signicant positive correla-
tions with HDL-cholesterol while simultaneously exhibiting 
negative associations with circulating triglyceride levels, in-
dicating that the thermogenic capacity of epicardial fat shares 
an association with the systemic metabolism in humans. Since 
then, we have expanded our work to investigate whether hu-
man epicardial fat represents a beige fat depot i.e. a fat de-
pot that carries UCP1 positive adipocytes, and is capable of 
upregulating leak respiration upon stimulation. Using direct 
tissue sampling and in-vitro di!erentiated primary adipocytes 
derived from patients undergoing heart surgeries, we have ob-
served that human epicardial fat carries the molecular signa-
tures of a beige fat depot and can be stimulated to upregulate 
its thermogenic machinery. Our preliminary observations of 
the presence of natriuretic peptide receptors and beta-klotho 
in epicardial fat further suggest that it could serve as the ther-
mogenic target site for circulating peptides such as natriu-
retic peptides and FGF21. "e relevant question of whether 
the thermogenic properties of epicardial fat can be targeted 





Laboratory of Clinical Immunology and St Marina University Translational Research Center, Varna, Bulgaria
Correspondence: tuckata@gmail.com
e importance of epigenetics for health and disease is widely 
recognized. Epigenetic factors play as important role in de-
termining phenotype as genetic factors are and can also be 
heritably transmitted to successive generations. Technological 
advances in epigenome proling caused increase of research 
in the eld of epigenetics in obesity. Obesity and related car-
diometabolic diseases such as atherosclerosis, hypertension, 
type 2 diabetes and metabolic syndrome are associated with 
epigenetic changes. ere is also evidence that early life en-
vironmental exposures (including in utero) can lead to sta-
ble alterations in the epigenome leading to increased risk of 
obesity later in life. Risk factors other than nutritional, like 
in!ammation, hyperglycemia and oxidative stress also seem 
to be linked to these epigenetic changes. Epigenetic research 
currently has several major objectives: (i) to identify epige-
netic biomarkers predictive for future risk of development of 
obesity, (ii) to identify environmental factors, associated with 
obesity, and (iii) to nd therapeutic, nutritional and/or phar-
macologic designs that could modify the epigenome. e rst 
feasible epigenetic markers detectable at birth have been iden-
tied and predicting obesity at this age is a prerequisite for tar-
geted prevention strategies. It has been shown that changing 
exposure in utero and changes in adult lifestyle can modify the 
adverse epigenetic proles. Active ingredients able to modify 
the epigenome and their doses and also optimal period of life 
for interventions need to be identied. is new layer of our 
understanding of obesity holds promise for more elegant and 
e"ective treatment.
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OLIVE POLYPHENOLS’ ROLE IN REGULATING METABOTROPHINS  
AS NGF AND BDNF 
Marco Fiore1, Valentina Carito1, George N. Chaldakov2, Mauro Ceccanti3
1Institute of Cell Biology and Neurobiology, CNR, Roma, Italy, 2Laboratory of Cell Biology,  
Department of Anatomy and Histology, Medical University, Varna, Bulgaria, 3CRARL Lazio. Sapienza University 
Hospital, Roma. Italy
Correspondence: marco.!ore@cnr.it
Polyphenols are probably the most known and investigated 
molecules of nutrition interest and they are micronutrients 
present in abundance in our diet. Some of the most important 
food sources of polyphenols are olives and olive oil. A grow-
ing body of evidence from animal models and clinical stud-
ies indicates that polyphenols have neuroprotective eects 
in various pathological states of the nervous system through 
the control of oxidative stress, inammation, apoptosis, mi-
tochondrial dysfunction. Also at peripheral level, they act as 
antioxidant, defending tissues against oxidative damage and 
scavenging free radicals. Moreover they prevent cardiovas-
cular disease by regulating the plasma levels of oxided LDL, 
decrease postprandial triacylglycerols, increase HDL and have 
also anti-thrombotic eects.  Additionally, a number of recent 
experimental and clinical data suggest that olive polyphenols 
are able to alter the expression of the neurotrophins nerve 
growth factor  (NGF) and brain-derived neurotrophic factor 
(BDNF) primarily known as biological mediators stimulating 
neuron growth, survival and dierentiation (1-4) and recently 
studied also as metabotrophins, acting on glucose, energy, 
pancreatic beta cells and cardiovascular homeostasis (5). In 
this context, better understanding the eects of polyphenols 
on these neuro-metabotrophic molecules certainly could 
generate interest for drug discovery and also for the potential 
dietary prevention of several cardiometabolic and neurode-
generative diseases.
1. Ceccanti M, Carito V, Iannuzzi S, Tarani L, De Nicolo’S, 
Ciafre’ S, Tirassa P, Capriglione I, Coriale G, Iannitelli A, 
Chaldakov GN, Fiore M. Serum BDNF and NGF modula-
tion by olive polyphenols in alcoholics during withdrawal. 
J Alcohol Drug Dep 2015 (in press) 
2. Carito V, Venditti A, Bianco A, Ceccanti M, Serrilli AM, 
Chaldakov G, Tarani L, De Nicolò S, Fiore M. Eects of ol-
ive leaf polyphenols on male mouse brain NGF, BDNF and 
their receptors TrkA, TrkB and p75. Nat Prod Res 2014; 28: 
1970-1984.
3. De Nicoló S, Tarani L, Ceccanti M, Maldini M, Natella F, 
Vania A, Chaldakov GN, Fiore M. Eects of olive poly-
phenols administration on nerve growth factor and brain-
derived neurotrophic factor in the mouse brain. Nutrition 
2013; 29: 681-687. 
4. Carito V, Ceccanti M, Chaldakov G, Tarani L, De Nicolò 
S, Ciafre’ S, Tirassa P, Fiore M. Polyphenols, nerve growth 
factor, brain-derived neurotrophic factor and the brain. In: 
Bioactive Nutriceuticals and Dietary Supplements in Neuro-
logical and Brain Disease: Prevention and !erapy. Watson 
RR, Preedy VR, editors. 2014. Elsevier pp 65-71.
5. Chaldakov GN, Fiore M, Hristova MG, Aloe L. 
Metabotrophic potential of neurotrophins: implication 




OSTEOCALCIN IN A RAT MODEL OF METABOLIC SYNDROME
Maria Zhleyazkova-Savova1, Silvia Gancheva1, Bistra Galunska2
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Recently, a research group led by Gerard Karsenty at Columbia 
University in New York, USA has demonstrated that bone is 
an endocrine organ that secretes a multifunctional hormone, 
osteocalcin (OC), and proposed a regulatory circuitry involv-
ing bone, pancreas, adipose tissue and brain in maintaining 
energy homeostasis in mice (1). e principal hormonal role 
in this loop has been ascribed to OC. is osteoblast-derived 
(and vitamin K dependent) protein has been shown to induce 
insulin secretion and beta cell proliferation and to improve in-
sulin sensitivity. It also increases adiponectin and decreases 
leptin release from the adipocytes. Osteocalcin has been pos-
tulated to be metabolically active in mice in its un(der)car-
boxylated form. is groundbreaking research was immedi-
ately reected by clinical studies that were undertaken to test 
the hypothesis in humans. Results are so far inconsistent and 
equivocal. Although in general many papers have reported 
various associations between OC and parameters of energy 
metabolism, serious discrepancies still exist in the literature 
as to which form of OC, the carboxylated or the un(der)car-
boxylated one, is responsible for the metabolic activity in man. 
Whether OC serves a similar metabolic role in the rat is 
currently unknown. In this pilot study we looked at OC in 
rats fed Western type hyper-caloric diet to develop a condition 
similar to metabolic syndrome (MS) in humans.
Two groups of rats were used. e control group received 
regular rat chow and plain water throughout the experi-
ment. e experimental group was fed high fat (17 % lard) 
and high (17 %) fructose (HFHF) diet and had 10% fructose 
in their drinking water. e duration of the experiment was 
10 weeks.  Insulin tolerance test (ITT) was performed at the 
end of the experiment; serum lipids were measured; serum 
insulin, leptin and both forms of OC – carboxylated and ud-
ercarboxylated, were determined by ELISA kits. HOMA-IR 
was calculated.
Body weight of the animals did not dier aer 10 weeks of 
dieting, but the diet manipulated rats had higher caloric in-
take. e metabolic syndrome induced by HFHF feeding was 
veried by increased visceral adipose tissue, elevated serum 
triglycerides (TGs) and blood glucose, positive ITT at the 90th 
minute, higher insulin and leptin levels. Undercarboxylated 
osteocalcin (ucOC) in the serum was reduced in the HFHF 
rats, whereas carboxylated osteocalcin (cOC) was slightly and 
insignicantly increased. e ratio ucOC/cOC was also lower 
in the experimental group. Undercarboxylated osteocalcin 
and ucOC/cOC were inversely associated with blood glucose 
in the HFHF group. No associations were found between 
ucOC and insulin, leptin, visceral adipose tissue or TGs. Car-
boxylated OC showed no correlation with any of the meta-
bolic parameters examined. 
Our preliminary results support partly the hypothesis that 
ucOC might be implicated in energy regulation also in the rat. 
In this animal species the undercarboxylated form of OC is 
probably the metabolically active one. Nevertheless, compared 
to the reported eects in mice, OC in rats seems much less ac-
tive. More evidence is necessary to conrm the hormonal role 
of OC in the rat. 
1. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux 
C, et al. Endocrine regulation of energy metabolism by the 
skeleton. Cell 2007; 130:456-469.
Adipobiology 7, 2015
614th International Symposium on Adipobiology and Adipopharmacology (ISAA)
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA:  
ANOTHER EXAMPLE OF ADIPOSE TISSUE RELATED DISEASES – 
INVOLVEMENT OF NEUROTROPHINS
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Arrhythmogenic right ventricular dysplasia (ARVD), also 
known as fatty degeneration of right heart, is a heritable disor-
der characterized by progressive degeneration and bro-fatty 
replacement of right ventricular myocardium, causing electri-
cal instability of the right ventricular myocardium, ventricular 
tachyarrhythmia and sudden death at a young age (1). Sev-
eral lines of evidence suggest that impairment of cardiomyo-
cyte adhesions (desmosomal proteins) may be the underlying 
pathogenic mechanism via accelerating apoptosis of these 
cells (2), but ARVD pathogenesis is still unclear (3). Since (i) 
adipose tissue replacement of cardiomyocytes is the most es-
sential histological nding in ARVD, and (ii) nerve growth 
factor (NGF) exerts an arrhythmogenic e!ect related to sud-
den cardiac death (4), the aim of the present study was to ana-
lyze immunohistochemically ARVD-related adipocytes with 
special attention to the expression of NGF and related neu-
rotrophins, brain-derived neurotrophic factor (BDNF) and 
neurotrophin-3 (NT3) and their respective TrkA, TrkB and 
TrkC receptors. Eight cases with ARVD were autopsy proven. 
"e present results show that the intramyocardial adipocytes 
in ARVD expressed these neurotrophins and their receptors, 
thus suggesting that they may play a substantial part in life-
threatening myocardial electrical instability.
1. "iene G, Corrado D, Basso C. Arrhythmogenic right ven-
tricular cardiomyopathy/dysplasia. Orphanet  J Rare Dis 
2007; 2: 45-61  DOI:  10.1186/1750-1172-2-45
2. Yang Z, Bowles NE, Scherer SE, Taylor MD,  Kearney DL, 
Ge S,  et al. Desmosomal dysfunction due to mutations 
in desmoplakin causes arrhythmogenic right ventricu-
lar dysplasia/cardiomyopathy. Cir Res 2006; 99: 646-655. 
PMID:16917092
3. Awad MM, Calkins H, Judge DP. Mechanisms of Disease: 
molecular genetics of arrhythmogenic right ventricular 
dysplasia/cardiomyopathy. Nat Clin Pract Cardiovasc Med 
2008; 5: 258-267. DOI:  10.1038/ncpcardio1182
4. Cao JM, Chen LS, Knight BH, Ohara T, Lee MH, Tsai J, 




PTEN, HSP27 AND NFkB IN ATHEROSCLEROSIS -  
AN IMMUNOHISTOCHEMICAL STUDY
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Phosphatase and Tensin homologue deleted on chromo-
some10 (PTEN) is a multifunctional tumour suppressor gene.It 
mediates several cell functions such as migration,proliferation 
and apoptosis.ese are mediated by antagonism of the phos-
phatidyl inositol 3 kinase (p13k) mediated signalling pathway.
In atherosclerosis inammatory cytokines and chemokines 
play important roles in cell proliferation and migration. Over-
expression of PTEN reduced neointima formation in associa-
tion with inhibition of macrophage invasion,cell proliferation 
and expression of proinammatory cytokines in addition to 
suppression of cell proliferation,migration and  increased ap-
optosis.
Heat shock proteins(HSPs) are molecular chaperones that 
protect against stress stimuli inducing heat shock,oxidised 
LDL, mechanical stress,oxidants and cytokine stimulation.
HSP27 belongs to the small HSPs family.It inhibits F-actin 
polymerisation, protects against apoptosis,and it presents 
oxidised proteins to the proteosome degradation machinery.
HSP27 expression is increased in the normal appearing ves-
sel adjacent to an athersclerotic plaque.Factors which enhance 
the production of HSPs  may necessarily lead to  reduced pro-
liferation of smooth muscle cells and  control the plaque size. 
Nuclear factor kappa B(NFkB) is a transcription factor which 
mediates the production of inammatory cytokines by vas-
cular cells,monocyte adhesion and proliferation,migration 
and proliferation of smooth muscle cells.Its activation leads 
to an increase in expression of many cytokines,adhesion 
molecules and enzymes involved in inammation and pro-
liferation.Activation of NFkB is an early event in athero-
sclerosis.It is present in brotic thickened intima media and 
atheromatous areas including smooth muscle cells, mac-
rophages and endothelial cells whereas it is totally absent in 
nonatheromatous areas of the vessel.Several cytokines such 
as TNFalpha and Interleukin-1 are able to activate NFkB in 
vitro.Activated NFkB may also modulate the chemotactic 
substance produced by the endothelial cells,such asMCP-
1(monocyte chemotactic protein-1) that attracts leucocytes 
to the lesion.Activation of signalling pathways by NFkB me-
diates cell survival mechanisms and contrarily it could also 
modulate pathways leading to cell degeneration,aging, dis-
ease and death. 
Immunohistochemistry of the  atherosclerotic lesions.e 
study of the aterosclerotic lesions in dierent stages and com-
paring it to the normal vessel with the help of immunohisto-
chemical staining using the appropriate antihuman antibodies 
against the above proteins would help us to locate the proteins 
and predict the outcome of the disease .e presence of PTEN 
and HSP 27 are good pointers to the absence of the disease 
whereas presence of NFkB would be an indicator of athero-
sclerotic vessel disease. Besides  immunohistochemistry could 
also prove to be a good  tool for the assured presence of vessel 
disease and in some cases point out the presence of an early 
plaque.  is could be used as a useful adjunct to the other 
diagnostic procedures in the  pathology laboratory.
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NUCLEAR RECEPTORS RXR AND LXR IN BRAIN –  
MORE THAN LIPID METABOLISM
Iliya Lefterov
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e research on the biology and function of the family of tran-
scription factors called nuclear receptors (NRs) has inuenced 
and changed dramatically our understanding of basic regula-
tory and metabolic pathways. e therapeutic implications of 
this knowledge are enormous. Most of those nuclear recep-
tors can not do their job alone, however, and their regulatory 
function is in fact executed while bound to DNA response 
elements as permissive heterodimers with Retinoid X Recep-
tors (RXRs). Some of the most prominent examples of the so 
called Class II NRs that require RXR for heterodimerazition 
are PPAR, LXR and TR. In the last 3-4 years a signicant at-
tention has been directed towards RXR for several reasons: 
A) in addition to working as heterodimers with other NRs, 
RXR form homodimers; B) RXR/RXR homodimers may 
have their own responsive genes, or once activated may ac-
tivate genes, traditionally considered LXR/RXR, PPAR/RXR 
or even targets genes of the non-permissive RAR/RXR het-
erodimers; C) there are synthetic and receptor type specic 
RXR ligands - one of them Bexarotene (Targretin) that have 
been FDA approved and for many years now in clinical use. 
Importantly it has been shown repeatedly, that ligand-acti-
vated RXR ameliorate memory decits in Alzheimer’s disease 
mouse models including mice expressing human APOE iso-
forms. ere has been however, incomplete understanding 
about molecular mechanisms underlying the e!ect of those 
ligands in the brain, moreover, the cognitive impairment in 
di!erent mouse models does not correlate to Aβ deposition 
in brain parenchima or vasculature. I will present the very 
recent research in our laboratory with the goal to gain further 
insight into molecular mechanisms whereby ligand-activated 
RXR can a!ect or restore cognitive functions. Our overall un-
biased approach is based on revealing genome-wide chang-
es in RXR cistrome (ChIP-seq) and gene expression prole 
(RNA-seq) in response to bexarotene in the cortex of APOE4 
mice. e results of Next Generation Sequencing have been 
accordingly validated and further used to examine Function-
al Gene Ontology categories enriched in both data sets and 
they show bexarotene-liganded RXR a!ect signaling path-
ways associated with neurogenesis and neuron projection 
development. Further validation assays in mouse embryonic 
stem cells (ES), primary neurons and APOE3 and APOE4 
mice treated with bexarotene conrm the results. Altogether 
the results of our studies on the role of bexarotene-activated 
RXRs in brain provide further evidence that they promote 
genetic programs involved in neurogenesis and development 
of neuronal projections with signicance for improvement of 




ADIPOCYTES AS BIOLOGICAL PROMOTERS OF WEIGHT REGAIN  
AFTER WEIGHT LOSS
Edwin Mariman, Roel Vink, Nadia Roumans, Freek Bouwman, Johan Renes, Marleen van Baak
Dept. Human Biology, NUTRIM, Maastricht University, The Netherlands
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Losing weight is an appropriate way for obese subjects to sig-
nicantly improve their health status and reduce morbidity 
risk. A popular method is taking a low calorie diet, which is 
oen successful. Unfortunately, up to 80% of people do not 
succeed in keeping their weight at the reduced level. is 
weight regain is usually attributed to psychosocial inuences. 
However, we propose that structural and metabolic changes 
in adipocytes during weight loss increase the risk for weight 
regain. One such change is that during, or shortly aer weight 
loss, adipocytes increase their capacity for uptake of fat. Dur-
ing weight loss, adipocytes lose fat and shrink. We suppose 
that under a negative energy balance, the extracellular matrix 
(ECM) cannot match this reduction in volume. As a conse-
quence, traction occurs between the ECM and the cell, which 
generates cellular stress. One way to reduce this adipocyte 
stress is by accumulating fat and allowing the cells to return 
to their original volume. is can be achieved by adjusting the 
adipokine levels. Figure 1 provides a schematic overview of 
our hypothesis. Experiments have been done to provide evi-
dence for this hypothesis. First, we have investigated if indeed 
cellular stress in adipocytes rises during weight loss, both in 
vivo and in vitro. Second, we have searched for genetic asso-
ciation between the risk for weight regain and genes coding 
for ECM-components.
Adipose tissue biopsies were taken from subjects that lost 
10% body weight in 5 weeks on a very-low caloric diet. Weight 
was measured again 10 months aer the weight loss phase. 
Levels of stress proteins were determined by Western blotting 
before and aer weight loss. In parallel, SGBS cells were glu-
cose-restricted for 4 days and levels of the same stress proteins 
were determined. For the genetic association study, SNPs in 
and around 129 genes coding for ECM proteins in adipocytes 
were analysed for association with weight regain/maintenance 
aer weight loss.
Aer weight loss, the level of some of the stress proteins 
was signicantly higher in the group of subjects that regained 
weight than in those who maintained the reduced weight. is 
included beta-actin and HSP27, which are related to so-called 
stress bers.
Genetic association was detected between weight regain 
and ve ECM-genes with di!erences between males and fe-
males.
Our ndings are in keeping with a model in which adipo-
cyte cellular stress, accumulating during weight loss, is related 
to the risk for weight regain. Moreover, our genetic observa-
tions are in line with a role for the ECM in the risk for weight 
regain.
Figure 1. A model for weight regain via adipocyte cell stress.
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ADIPONECTIN – A POSSIBLE LINK BETWEEN AGEING, METABOLIC STRESS 
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Ageing is associated with numerous hormonal changes aect-
ing the energy metabolism and sensitivity to insulin. Evidence 
suggests that a clustering of sources of oxidative stress exists 
in obesity: hyperglycemia, hyperleptinemia, increased tissue 
lipid levels, inadequate antioxidant defenses, increased rates 
of free radical formation, enzymatic sources within the endo-
thelium, and chronic inammation. Adiponectin is a highly 
abundant insulin sensitizing, anti-inammatory, and anti-
atherogenic protein hormone produced exclusively by adipo-
cytes. e aim of the present study is to explore the potential 
link between circulating levels of adiponectin, general meta-
bolic prole, endothelial function, and systemic glycoxidative/
lipoxidative stress in elderly subjects with type 2 diabetes and 
hyperlipidemia. 
53 subjects (11 men and 42 women, aged 60+17 years), 
hospitalized at NIGG „Ana Aslan”, were divided in two study-
groups: a control group (n=23), including healthy patients 
with normal values of biochemical and hematological pa-
rameters; a group of patients with impaired fasting glucose 
(IFG) or type 2 diabetes  mellitus (DM2) and hyperlipidemia 
(n=30). Serum adiponectin levels were evaluated together 
with a biochemical marker of endothelial dysfunction - ni-
tric oxide metabolic end products NOx [NO2- + NO3-], and 
serum oxidative stress parameters: Advanced Oxydation and 
Glycation Protein Products (AOPPs and AGEs), total oxida-
tive and antioxidative capacity (TOC and TAC), low density 
lipoprotein susceptibility to lipid peroxydation (LDLox).
Our results clearly pointed out signicant lower levels of 
adiponectin in elderly hyperglycemic subjects compared with 
healthy age-matched group, concomitantly with signicantly 
higher levels of oxidative stress and endothelial dysfunction 
markers. As well, patients with chronic hyperglycemia had 
signicantly higher NOx values compared with the control 
group. Lipid and lipoprotein parameters and not glycemia, 
were the main metabolic determinants of adiponectin. Serum 
levels of adiponectin positively and signicantly correlated 
with HDL-cholesterol as well as with total cholesterol, both in 
hyperglycemic subjects and in all study population. Stratied 
analysis according to serum adiponectin levels, in all study 
subjects (n=53) showed signicantly higher values of AOPP, 
LDLox and NOx, for subjects with lower adiponectin levels 
(< 14 ng/ml).
e marked increases in oxidative stress markers in impaired 
glucose metabolism elderly subjects could be due to cumulative 
eects of adiponectin secretion deciency and HDL reduced 
levels, which both contribute to the decrease in antioxidant ac-
tivity, favoring oxidative processes. Adiponectin in combination 
with NOx, LDLox and AOPP appear to be important biomark-
ers for evaluating the association between metabolic imbalance 
and systemic oxidative stress in elderly patients.
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FROM ADIPOSE TISSUE TO THE BONE – OUR EXPERIMENTAL STUDIES
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Adipose tissue, in addition to other cellular components, is 
also a rich source of adult stem cells, thus being an important 
candidate for participation in the regenerative medicine and 
tissue engineering. In our experimental studies of bone regen-
eration and bone tissue engineering, we used adipose tissue in 
a number of ways and in a several experimental models. 
With the components of adipose tissue, we used mineral 
bone matrix as a carrier for the cells or as a scaold for new 
bone tissue. We have used blood components such as platelet-
rich plasma as a supplement to such constructs in some of the 
studies1,2. We have also made preliminary experiments with 
3D printed scaolds of bone tissue. Adipose tissue was used in 
various forms such as chopped whole tissue, freshly isolated 
stromal vascular fraction, expanded adipose-derived stem 
cells (ADSCs) as well as ADSCs in vitro osteo-induced1 and 
induced into endothelial cells2. !e potential of the adipose 
tissue in the bone formation were studied in orthopic and ec-
topic osteogenic models in rabbits, mice and rats, as well as in 
cell cultures in vitro. Assessment of osteogenic potential was 
performed using numerous methods including histological 
staining, morphometry, immunohistochemistry, radiographic 
and analytical methods, analysis of speci"c gene expression, 
various in vitro methods and others1,2. All experiments have 
shown that adipose tissue expressed osteogenic potential, so 
that it can participate in the formation of new bone, induc-
ing, enhancing and favoring osteogenic process. Components 
of adipose tissue and forms in which they were applied have 
shown osteogenic potential in dierent degree and expressed 
it in dierent ways1,2. 
!e obtained data may be applicative in regenerative medi-
cine of skeletal system because they may help in the choice of 
a way of using the adipose tissue in accordance with the goal 
of treatment. 
!is study was supported by the Ministry of Education, 
Science and Technological Development of the Republic of 
Serbia (Grant No. III 41017). 
1. Vladimir J. Cvetković, Jelena G. Najdanović, Marija Đ. 
Vukelić-Nikolić, Sanja Stojanović, Stevo J. Najman. Osteo-
genic potential of in vitro osteoinduced adipose-derived 
mesenchymal stem cells combined with platelet-rich plas-
ma in ectopic model. Int Orthopaed 2015 Aug 01 [Epub], 
DOI 10.1007/s00264-015-2929-x.
2. Jelena G. Najdanović, Vladimir J. Cvetković, San-
ja Stojanović, Marija Đ. Vukelić-Nikolić, Milica N. 
Stanisavljević, Jelena M. Živković, Stevo J. Najman. !e 
In&uence of Adipose-Derived Stem Cells Induced into En-
dothelial Cells on Ectopic Vasculogenesis and Osteogen-
esis. Cell Mol Bioeng  2015 Jun 30 [Epub], DOI: 10.1007/
s12195-015-0403-x.
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PHENOTYPE MODULATION IN BROWN ADIPOSE TISSUE:  
BEIGE, BRITE AND BRUSCLE ADIPOCYTES
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is lecture aims to cover some aspects of the recent progress 
in our understanding of the anatomical, developmental, po-
tential dierences in responsiveness and functional character-
istics of brown, beige and bruscle adipocytes, with a special 
emphasis on adult human brown adipose tissue (BAT). e 
attitude that white adipose tissue (WAT) has merely lipid stor-
age and supporting functions has been completely changed in 
the last decades. Now, WAT is identied as a dynamic endo-
crine and paracrine organ secreting pro- and anti-inamma-
tory signaling proteins (adipokines), the adipokine imbalance 
leading to cardiometabolic diseases. Contrary, BAT may be 
considered as a health-promoting organ suppressing the de-
velopment of these diseases through its thermogenic function 
(1). Brown adipocytes burn glucose and lipids to maintain 
thermal homeostasis and dissipate energy to produce heat 
through nonshivering thermogenesis, via mitochondrial un-
coupling proteins. ermogenic adipocytes are classied as 
classical brown adipocytes and beige (also referred to as brite) 
adipocytes with distinct developmental and anatomical fea-
tures. Brown adipose tissue was considered to be present and 
active in prematures, neonates and young children generat-
ing heat and helping thermoregulation; it may transform into 
WAT, known as brown-to-white transdierentiation (2). e 
main BAT depots are disseminated throughout the human 
body (around the aorta, common carotid artery, brachioce-
phalic artery, around epicardial coronary artery, in anterior 
mediastinum, supraclavicular fossa, axilla, thoracic paraver-
tebral loci, between neck muscles) (3). Some new data suggest 
that brown adipocytes might be interspersed in WAT of ro-
dents and humans to form ‘beige cells’ or ‘brite fat cells’(brown 
in white) as a result of chronic cold exposure (4-6).
In eect, these new data might be implicated in BAT-focused 
strategies in the prevention and therapy of obesity and related 
cardiometabolic diseases. 
1. Frontini A, Cinti S. Distribution and development of brown 
adipocytes in the murine and human adipose organ. Cell 
Metab 2010; 11: 253-256.
2. Sacks H, Symonds ME. Anatomical locations of human 
brown adipose tissue: functional relevance and implica-
tions in obesity and type 2 diabetes. Diabetes 2013; 62: 
1783-1790.
3. Harms M, Seale P. Brown and beige fat: development, func-
tion and therapeutic potential. Nat Med 2013; 19: 1252-
1263.
4.  Rančić G, Fiore M, Pancheva R, Tunçel N, Beltowski J, Zhe-
lezov M, et al. Adipose tissue: the Renaissance marked by 
four paradigm shi$s.  Adipobiology 2014; 6:49-53.
5.  Carobbio S, Rosen B, Vidal-Puig A. Adipogenesis: new in-
sights into brown adipose tissue dierentiation. J Mol En-
docrinol  2013, 51 (3) T75-T85.
6.  Giralt M, Villarroya F. White, brown, beige/brite: Dierent 




OBESITY AND CANCER, ROLE OF ADIPOKINES IN CANCER 
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Obesity is associated with cancer development and progres-
sion. Meta-analyses showed that the risk for several types of 
cancer increased with 6-59% with every increment of 5 kg/m2 
in BMI above normal levels. Vice versa, weight loss reduces the 
risk for cancer. Epidemiological studies further indicated that, 
next to cancer development, cancer progression is worsened 
in obese subjects. Cancer progression is particularly driven by 
metastasis. While the association between obesity and cancer 
is increasingly evident the molecular mechanisms involved in 
obesity-mediated neoplasia and/or metastasis are still elusive. 
One hypothesis states that fat tissue in close proximity with tu-
mors forms a permissive microenvironment. is is explained 
by cancer-mediated lipolysis, which gradually changes adipo-
cytes into cancer-associated broblasts (CAF’s). Subsequently, 
the secretome of these CAF’s is altered with increased expres-
sion of pro-inammatory adipo(cyto)kines. An alternative 
hypothesis is that obesity-induced alterations in circulating 
adipokines levels may result in elevated cancer risk. Decreased 
adiponectin and increased leptin levels directly aect cancer 
development and progression in in vitro and in vivo models. 
Despite the established relation between weight gain/loss and 
cancer, the potential metastasis-inducing eect of the human 
adipocyte secretome is barely investigated. 
Hallmarks of metastasis are invasion and migration of pri-
mary tumor cells to distal sites to form secondary tumors. e 
migration potential of human adipocyte secretomes on hu-
man HT-29 colorectal adenocarcinoma cells was investigated 
with a coculture system (see Figure 1). HT-29 cells were incu-
bated for 48 hrs with conditioned medium derived from SGBS 
preadipocytes, SGBS adipocytes and SGBS adipocytes starved 
for 4d and 20d. Migrated cells were detected with a crystal 
violet assay. e SGBS secretomes were analyzed by liquid 
chromatography tandem mass spectrometry (LC-MSMS) to 
identify the secreted proteins.
Compared to the preadipocyte secretome, the adipocyte se-
cretome signicantly induced HT-29 cell migration. With the 
secretomes of starved adipocytes migration of HT-29 cells was 
comparable with the migration observed with the preadipo-
cyte secretome. Proteome analysis of the secretomes revealed 
that the SGBS adipocyte secretome contains several proteins 
with functions related to cellular proliferation and migration.
Secretomes of human subcutaneous adipocytes induce mi-
gration of human colorectal adenocarcinoma cells. is eect 
can be reduced by starvation.  ese results indicate that obe-
sity may induce colorectal cancer metastasis.  
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IMAGING HEART-ASSOCIATED ADIPOSE TISSUE BY LATEST GENERATION  
DUAL-SOURCE-COMPUTED TOMOGRAPHY CT FORCE: PRELIMINARY DATA
Roman Sokiranski1, Vesselka Nikolova2, Anton B. Tonchev3
1Radiologisches Zentrum Heidelberg, 2Kirchberg Klinik, Bad Lauterberg, Germany, 
3Department of Anatomy and Histology, Medical University, Varna, Bulgaria
Correspondence: Sokiranski@gmx.net 
Recently, the signicance of blood vessel- and heart-associat-
ed adipose tissue (epicardial, pericardial, periadventitial and 
intramyocardial) in the pathogenesis of atherosclerosis is in-
creasingly pursued both at experimental and clinical level (1, 
2). As a part of scientic collaboration between the Medical 
University in Varna and the Radiological Center in Heidel-
berg asymptomatic patients are examined for risk assessment 
of coronary artery disease. e investigations are carried out 
with a new spiral CT (computed tomography) Twin Beam 
Dual Energy technology CT force. In contrast to the conven-
tional CT devices, the heart examination takes place in a very 
short time (0.15 sec.), in low dose technology with reduction 
of radiation exposure by 90 % (0.1 to 0.6 ms) and in a very 
high spatial and temporal resolution (0.25 mm / 160 ms). 
Since this novel imaging technique allows the very fast acqui-
sition of more detailed parameters, this can be translated into 
more precise representation and quantication of pericardial 
and epicardial adipose tissue. We provide the rst results of 
cardiac adipose tissue imaging with this technique. In just one 
examination sequence taking less than a second this method 
provides calcium score by CT angiography of the coronary 
arteries as well as the three-dimensional morphology of the 
epicardial adipose tissue.
1. Chaldakov GN, Fiore M, Ghenev PI,  Beltowski J, Rancic G, 
Tunçel  N, Aloe L. Triactome: neuro-immune-adipose in-
teractions. Implication in vascular biology. Front Immunol 
2014; 5: 130. DOI: 10.3389/mmu.2014.00130
2.  Yañez-Rivera TG, Baños-Gonzalez MA, Ble-Castillo JL, 
Torres-Hernandez ME, Torres-Lopez JE, Borrayo-Sanchez 
G. Relationship between epicardial adipose tissue, coro-
nary artery disease and adiponectin in a Mexican popula-
tion. Cardiovasc Ultrasound 2014; 12: 35.
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DIFFERENT ADIPOGENIC POTENTIAL OF MESENCHYMAL STEM CELLS ISOLATED 
FROM LIPOMA AND NORMAL ADIPOSE TISSUE - A PRELIMINARY RESULTS
Sanja Stojanović1, Stevo Najman1, Aleksandra Korać2
1Department for Cell and Tissue Engineering and Department for Biology and Human Genetics,  
Faculty of Medicine, University of Niš, Niš, Serbia
2Institute of Zoology and Center for Electron Microscopy, Faculty of Biology, University of Belgrade,  
Belgrade, Serbia
Lipoma is a benign adipose tissue tumor that most frequent-
ly appear in the subcutaneous tissue. It has been shown that 
adipose-derived stem cells (ADSCs) isolated from lipoma tis-
sue (LDSCs), exhibit characteristics similar to ADSCs isolated 
from normal adipose tissue. ey are morphologically simi-
lar, express characteristic mesenchymal stem cell markers and 
have the potential to dierentiate into multiple lineages such 
as adipocytes, osteoblasts and chondrocytes.  e aim of our 
study was to examine whether LDSCs have the same potential 
to dierentiate into adipocytes as ADSCs. 
Tissue samples were excised from the subcutaneous tu-
mor tissue or normal subcutaneous adipose tissue during 
surgery. Cells were isolated by enzymatic digestion and cul-
tured in standard cell culture conditions. Aer second passage 
both LDSCs and ADSCs were subjected to adipogenic dif-
ferentiation for 21 day. As negative control, cells were grown 
in standard cell culture media. Expression of characteristic 
mesenchymal stem cell markers, CD29 and CD44, was con-
rmed by immunocytochemical staining before subjecting to 
dierentiation. Adipogenic dierentiation was evaluated mi-
croscopically and by Oil Red O staining. Results: Both LD-
SCs and ADSCs were morphologically similar aer isolation 
and were positive for CD29 and CD44 mesenchymal stem cell 
markers. We have shown that LDSCs have weaker potential 
to dierentiate into adipocytes than ADSCs. Aer 21 day of 
dierentiation, both LDSCs and ADSCs were phenotypically 
dierent from cells that were grown in standard cell culture 
media and had characteristic shape, but there were less mature 
adipocytes lled with lipid droplets in LDSCs cultures than in 
ADSCs cultures. We can conclude that, in these conditions, 
LDSCs have weaker potential for dierentiation toward adi-
pocytes than ADSCs. is nding may contribute to the char-
acterization of lipoma and explanation of the mechanisms of 
its formation, although further investigation on molecular 
level is needed. 
is study was supported by the Ministry of Education, 
Science and Technological Development of the Republic of 
Serbia (Grant No. III 41017) 
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FATTY ACID RECEPTORS AND BINDING PROTEINS IN PROGENITOR CELL 
NICHE OF ADULT PRIMATE BRAIN
Anton B. Tonchev1, D. Ma2, Nadya Boneva2, Tetsumori Yamashima2, 
1Department of Anatomy, Histology and Embryology, Medical University, Varna, Bulgaria
2Kanazawa University, Kanazawa city, Japan
e adult brain harbors neural stem/progenitor cells (NPCs). 
ey exist in microenvironments known as progenitor cell 
niches. e subgranular zone (SGZ) of the hippocampal den-
tate gyrus and the subventricular zone (SVZ) along the an-
terior horn of the lateral ventricle are the two best described 
niches in the mammalian brain. Here we describe some puta-
tive molecular signals expressed in these microenvironments 
of the adult monkey hippocampus. e G-protein coupled 
receptor 40 (GPR40) is a transmembrane receptor for free 
fatty acids, involved in insulin secretion in the pancreas. In-
terestingly, we found a molecular link between dietary sig-
nals such as free fatty acids and adult neurogenesis by means 
of the free fatty acid receptor GPR40 being expressed in the 
precursor cell niche. Further, we identi!ed that fatty acid-
binding proteins (FABPs), a group of molecules known to 
participate in cellular metabolic processes, were expressed in 
the hippocampal neurogenic zones and in particular in the 
niche astrocytes. Our results suggest that while a complex 
network of secreted and nuclear signals regulates neurogen-
esis in adult primate hippocampus, some of them are related 
to dietary signals. e k nowledge on the mechanisms regu-
lating brain progenitors in adult primates would probably 




NERVE GROWTH FACTOR AND BRAIN-DERIVED NEUROTROPHIC FACTOR IN THE 
FAT FROM RATS WITH METABOLIC SYNDROME 
Myrian Velasco, Carlos Larqué, José Romo, Carmen Sánchez-Soto,  
Juan Pablo Chávez-Maldonado and Marcia Hiriart 
Department of Neurodevelopment and Physiology, Instituto de Fisiología Celular,  
Universidad Nacional Autónoma de México. Mexico D.F., Mexico
Obesity and the concomitant prevalence of metabolic syn-
drome (MS) and type 2 diabetes mellitus (DM2) had increased 
as a global epidemic during the last decades. e initial steps 
include low physical activity associated to high food con-
sumption that increment circulating lipids and cytokines, and 
growth factors release by adipose tissue. is, in turn cause 
chronic inammation and potentiation of insulin secretion, 
and insulin resistance.
Metabolic syndrome is a cluster of signs that increases 
the risk to develop DM2, cardiovascular diseases and cer-
tain types of cancer. e main signs of MS are central obesity, 
dyslipidemia, hypertension, hyperinsulinemia and insulin 
resistance. Depending on genetics, aer a long period of hy-
peractivity, pancreatic beta cells become exhausted and DM2 
overcomes.
Nerve Growth Factor (NGF) and Brain-Derived Neuro-
trophic Factor (BDNF) are neurotrophic factors that are also 
synthetize and liberated by white adipose tissue. We have pre-
viously observed that NGF is also produced and secreted by 
pancreatic beta cells, and increases insulin secretion; it is then 
possible that in obesity there is more NGF in extracellular me-
dia that could contribute to hyperinsulinemia. 
In this work we analyzed NGF plasma levels and NGF 
produced by peripancreatic (Ppf) and epididymal (Epf) fat 
during the development of MS. We also evaluated BDNF pro-
duced by the fat. We developed MS in Wistar adult male rats 
(2 months old) by feeding experimental rats with high sucrose 
(20%) in the drinking water, for 2 and 6 months and compared 
to controls.
Aer two months, treated rats developed MS, characterized 
by central obesity, mild hypertension, hypertriglyceridemia, 
hyperinsulinemia and insulin resistance (MS rats). is signs 
were also present aer 6 months of treatment; interestingly in 
the later they also showed fasting hyperglycemia.
Moreover, Ppf and Epf fat from MS rats, showed higher 
amounts of NGF than control rats, aer 2 and 6 months of 
treatment. e highest level of NGF was observed in Epf at 2 
months of treatment. Interestingly, in both treatments types, 
NGF amount in Epf was higher than in Ppf. e amount of 
BDNF signicantly increased in 6 months MS rats, in both 
adipose depots, compared to controls. Finally we also ana-
lyzed the fat mRNA expression pattern of some cytokines in 
fat from MS rats (6 months of treatment). We found a signi-
cant increase in the expression of IL6 in Ppf and Epf, and IL10 
in Epf, and a signicant decrease in resistin in Ppf.  
Our results demonstrate adipose changes of NGF, BDNF, 
IL6, IL10 and resistin that could be important in the biology 
of adipose tissue during obesity and metabolic syndrome, and 
probably in the physiology of pancreatic beta cells, and insulin 
secretion.
Acknowledgements. is work was partially supported by 
DGAPA-PAPIIT IN213114, UNAM.
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OBESE PATIENTS AS A CHALLENGE FOR PERSONALIZED MEDICINE:  
EXAMPLES FROM DRUG METABOLISM AND TOXICITY
Stanislav G. Yanev
Department of Drug Toxicology, Institute of Neurobiology, BAS, So!a, Bulgaria
Correspondence: stanislav_yanev@yahoo.com
e good physician cares for the disease;
the great physician cares for the patient.
Sir William Osler (1849-1919)
e term „personalized medicine“ is described as providing 
„the right patient with the right drug at the right dose at 
the right time.“ More broadly, personalized medicine may 
be thought of as the tailoring of medical treatment to the 
individual characteristics, needs, and preferences of a patient 
during all stages of care. In this respect obese persons are a real 
challenge to implement the new achievements of personalized 
medicine. In the present lecture some data will be given from 
the few examples for dierences of drug distribution and 
metabolism and the resulting dierences in drug eects and 
toxicity in obese persons. Some objectives for inconclusive 
results for personal pharmacotherapy in obese patients are 
that clinical trial protocols oen specically exclude obese 
patients, leaving the impact of obesity on the pharmacology 
of most drugs uninvestigated. Obesity and drug distribution: 
e main factors which aect the process of tissue distri-
bution of drugs are their physiochemical properties, body 
composition, plasma protein binding and regional blood 
!ow. An understanding of how the volume of distribution 
of a drug changes in the obese is critical, as this parameter 
determines loading-dose selection. Existing insu"cient 
clinical data show that highly lipophilic drugs like benzo-
diazepines, tricyclic antidepressants, antibacterials (cipro-
!oxacin), anticoagulants (dalteparin), anticancer drugs (bu-
sulfan, cisplatin, docetaxel, vincristine), oral anticonceptives 
(norethisterone and ethinylestradiol with failed eects) and 
volatile anesthetics (halothane with increased liver toxicity; 
en!urane with increased risks for !uoride nephrotoxicity), 
IFN-α (lower serum concentrations), were distributed more 
extensively in adipose tissue of obese patients, therefore, 
loading dosage may need to be increased and in the same 
time some adverse reactions should be carefully moni-
tored. Drug protein binding has not been demonstrated to be 
changed in obese persons. Obesity and drug metabolism and 
clearance: Drug clearance (CL) is the primary determinant to 
consider when designing a maintenance dose regimen. CL is 
largely controlled by hepatic and renal physiology. According 
to preliminary results of propofol, sufentanil and paclitaxel 
clinical studies, liver blood !ow is likely to be increased in 
obese patients. e reviewed studies show that clearance of 
renally eliminated drug is higher in obese patients because of 
increased glomerular ltration and tubular secretion. Clini-
cal data for changes in activity of various drug metabolism 
enzymes in obese patients are diverse: CYP 3A4 – reduced 
metabolic activity to N-methylerythromycin, midazolam, 
triazolam, alprazolam and ciclosporin, alfentanil; CYP 2E1 
– increased metabolic activity to chlorzoxazone, volatile 
anaesthetics, including en!urane, sevo!urane and halothane, 
paracetamol (increased liver toxicity); CYP 2D6 – increased 
metabolic activity to dexfen!uramine and nebivolol; CYP 
2A6 – increased metabolic activity to valproic acid, nicotine, 
methoxy!urane; CYP 1A2 – slight increased activity to the-
ophylline and caeine; CYP 2C9 – slightly increased activity 
to ibuprofen, phenytoin, and glipizide; CYP 2C19 – higher 
activity to diazepam; CYP 4A – increased fatty acids oxida-
tion; possible cause: enzyme genes expression is regulated 
by leptin receptor signaling. It is important to note that 
leptin treatment return to normal the changed CYP’s activity 
in obese animals, the eect is due either to a direct second 
messenger event or to indirect changes in insulin, cortisol, 
and/or growth hormone levels. It should be proven whether 
this occurs in obese persons. 
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CHANGES OF THE HYPOTHALAMIC PROOPIOMELANOCORTIN  
AND AGOUTI-RELATED PEPTIDE CONTENT IN RATS TREATED  
WITH SIBUTRAMINE UNDER HIGH-CALORIE DIET
Zagayko A, Briukhanova T, Kravchenko G, Shkapo A
National University of Pharmacy, Kharkiv, Ukraine
Obesity is a major health and social problem that is charac-
terized by high rate of distribution in the population. Under 
modern concepts the inuence on eating behavior is one of 
the promising ways to correct the obesity. Both central and 
peripheral mechanisms are involved in energy metabolism 
dysregulation under obesity. Hypothalamus is the main regu-
lation center of feeding behavior in the brain. Hypothalamus 
arcuate nucleus is the basic formation that regulates feeding 
behavior and contains two types of neuronal populations. 
e rst ones contain agouti-related peptide (AgRP), that 
stimulates the food intake, the others - proopiomelanocortin 
(POMC), that inhibits the feeling of hunger. Sibutramine is an 
anorexigenic preparation that inuences on the central cores 
of obesity development, but the mechanisms of inuence on 
the feeding behavior are not fully understood. erefore, the 
aim of our work was to study the eect of this preparation 
onto the AgRP and POMC content on hypothalamus of the 
rats fed high-calorie diet.
Adult male Sprague-Dawley rats weighing 250-300 g were 
used. ey were divided into three experimental groups: in-
tact animals (IG) that were fed a standard vivarium diet; rats 
that were fed high-calorie diet (model pathology – MP); rats 
that under high-calorie diet were administered sibutramine 
10 mg / kg for 3 weeks (MP + sibutramine). e hypothala-
mus was removed, weighed and placed into 0.25 ml of 0.1 M 
acetic acid, boiled and dispersed tissue by sonication. Tissue 
homogenates were neutralized with 100 mM Tris (pH 7.0) 
and centrifuged at 14 000 rpm for 10 minutes. e AgRP and 
POMC content were determined in homogenate by radioim-
munoassay kits (Phoenix Pharmaceuticals Inc., Mountain 
View, CA, USA).
e development of obesity was observed in rats fed high-
calorie diet, that was accompanied by a signicant increase 
of AgRP content (in 2.1 times) compared with animals from 
IG, conversely, the POMC content was signicantly lowered 
(see table). AgRP and POMC are endogenous antagonists, so 
such dynamics under MP is natural and is mediated by insulin 
resistance and hyperleptinemia that accompany obesity. e 
normalization of AgRP and POMC content observed in rats 
administered sibutramine was revealed by correction of eat-
ing behavior in animals and the prevention of obesity under 
high-calorie diet. Sibutramine is an inhibitor of reverse neu-
ronal uptake of serotonin and norepinephrine, and serotonin 
– in turn can stimulate the POMC secretion. In our previous 
studies we have shown the sibutramine inhibitory action on 
the neuropeptide Y eects, which acts synergistically with 
AgRP (Zagayko, 2015). In addition, sibutramine normalizes 
leptin and insulin levels under experimental insulin resistance 
(Derosa, 2010; Suliburska, 2012), and these hormones are in-
hibitors of the AgRP-containing neurons activity. is fact ex-
plains the AgRP decrease under sibutramine administration.







*   -  statistically signi"cant di#erence compared to the IG (р ≤ 0.01);
** -  statistically signi"cant di#erence compared to the MP (р ≤ 0.01).
Dynamics of the AgRP and POMC content changes indicates 
the sibutramine ability to correct obesity integrally, including 
normalizing of eating behavior, and as a consequence – the 
earlier feeling of satiety and prevention of overeating.
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THE TRIO: ADIPOSSE TISSUE, IMMUNE SYSTEM AND ISLET Β-CELLS
Constantin Ionescu-Tîrgovişte
National Institute of Diabetes, Nutrition and Metabolic Diseases “Prof. N.C. Paulescu” Bucharest, Romania
e parallel increase in the prevalence of diabetes and obe-
sity (recently dubbed diabesity) has been associated to the 
rapid environmental and social changes (1). e adipose tis-
sue represents the main lipid depot, which is essential for the 
maintenance of the energy homeostasis of the human body. 
e immune system as a member of the defence system of the 
body’s integrity is able to take part in the continuous surveil-
lance of the “normal” adipose depots, reacting adequately to 
the smooth passing of the “quiet” (normal) adipocyte, to the 
“restless” adipocyte and mainly to the “aggressive” adipocyte as 
we characterized them previously (2). e  adipocyte “aggres-
sive” phenotype is able to produce and release a high number 
of adipokines consisting of cytokines and chemokines acting as 
danger signals (3, 4) perceived by the immune system (dendritic 
cells !rst) inducing so called low grade in!ammation, with its 
multiple e"ects on the vascular endothelial cells in the heart, 
liver, kidney, brain, pancreatic islets, spleen, lymph nodes and 
other structures of the human body. By its big and dynamic se-
cretory function, producing more than 200 various signaling 
molecules, the adipose tissue has been characterized as “the 
third brain” and “a tissue with high intelligence quotient” (5). 
A great part of adipokines are considered to be derived from 
the adipose stromal vascular cells, explaining the great plastic-
ity of this huge secretory organ. Apart, adipose macrophages 
and dendritic cells as well as other immune cells (T and B 
lymphocytes, and mast cells) can also interact with adipo-
cytes. Notably, the dendritic cells (6) are present mainly in 
the omentum (uniquely mammalian structure) where, close 
interaction take place between the adipocyte layers up to 10 
mm surrounding the lymph nodes. In interesting cooperation, 
the adipocyte closer with lymph notes gain some lymphoidic 
phenotypes whereas, the external cell layer of lymph nodes 
gain some metabolic phenotype of the adipocyte (7). A simi-
lar behavior can be observed in the various compartments of 
the adipose tissue: perivascular, epi- and pericardial, peripan-
creatic, intra- and perimuscular, etc. e association between 
obesity ant type 2 diabetes mellitus shapes an “old couple” (8). 
e pathogenic link between the adipose tissue and pancreatic 
β-cell is insured by the proin$ammatory reaction triggered by 
the adipokines TNF-α, IFN-γ, IL-6, MCP1, CCR2, including a 
decrease in adiponectin and NGF secretion (5), all released by 
the aggressive adipocyte (9). 
1.  O’Rahilly S, Farooqi IS. Human obesity: A heritable neu-
robehavioral disorder that is highly sensitive to environ-
mental conditions. Diabetes 2008; 57:2905-2910.
2.  Ionescu-Tîrgoviste C, Gagniuc PA, Guja C. A challenge for 
the autoimmune diabetogenic mechanism in type 1 diabe-
tes? Acta Endocrinol (Bucharest) 2014; 10: 317-328. 
3.  Ionescu-Tîrgovişte C, Guja C, Gagniuc P. In debate: the 
primary cause of type 1 diabetes. Proc Rom Acad - Series B 
2014; 16:179-200. 
4.  Matzinger P. Tolerance, danger, and the extended family. 
Annu Rev Immunol 1994; 12, 991-1045.
5.  Chaldakov GN, Fiore M., Tonchev AB, Hristova MG, 
Rancic G, Aloe L. e adipose tissue as a third brain. Obes 
Metab 2009; 5: 94-96.
6.  Steinman R. Decision about dendritic cells: past, present 
and future. Annu Rev Immunol 2012; 30:1-22.
7.  Pond CM. Paracrine provision of lipids in the immune sys-
tem. Curr Immunol Rev 2009; 5:150-160.
8.  Ionescu-Tîrgovişte C, Cheţa D, Popa E, Mincu I. Le rôle de 
l’obesité dans l’etiopathogenie du diabète sucré. Medecine 
et Nutrition 1976; 12: 97-106.
9.  Ionescu-Tîrgovişte C. Insulin resistance - what is myth and 
what is reality? Acta Endocrinol (Bucharest)  2011; 7: 123-146. 
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A VICIOUS CONNECTION:  
ADIPOSE TISSUE-OBESITY-IMMUNE SYSTE-ATHEROSCLEROSIS
Maya Simionescu
Institute of Cellular Biology and Pathology “Nicolae Simionescu”, Bucharest, Romania
e cell constituents of the adipose tissue secrete a large num-
ber of bioactive adipokines that have endocrine, paracrine and 
autocrine eects. Adipocytes and adipose tissue-derived mac-
rophages are the source of the several circulating mediators of 
inammation. Excess or unbalanced secretion of adipokines, 
a frequent occurrence in obesity, induces an inammatory 
state that in turn contributes to obesity-associated cardiovas-
cular diseases. Atherogenesis occurs irrespective of the pres-
ence of dyslipidemia (conventional view) and inammatory 
cells have a key role in atherosclerosis that is now recognized 
as a subacute inammatory condition of the vessel wall. Ath-
eroma formation is a continuous process arbitrarily delineated 
by consecutive stages. 
Stage I. Commencement of plaque formation: modulation of 
endothelial cells (EC) constitutive functions: a. loss of EC con-
trolled permeability, increased transcytosis and intimal de-
position of plasma LDL; b. changes in EC phenotype, i.e. the 
switch toward a secretory type; c. alteration of EC net negative 
surface charge. 
Stage II. EC dysfunction and the initiation of a multipart 
inammatory process manifested by EC “activation”: altera-
tions of the EC non-adhesive and non-thrombogenic surface, 
expression of plasmalemmal new or additional cell adhesion 
molecules or inammatory mediators. EC activation and dys-
function, is a defence reaction assisting the vascular endothe-
lium to recruit speci!cally blood inammatory cells. 
Stage III. Robust inammatory reaction: adhesion and 
extravasation of monocytes and lymphocytes, fatty streak 
formation: a. Adhesion, diapedesis and intimal residence of 
pro-inammatory monocytes; platelets assist the recruitment 
of blood monocytes; b. Recruitment of circulating T-Lympho-
cytes (CD4+T cells) together with antigen-presenting dendritic 
cells in response to chemokines and chemoattractants. Upon 
recognition of an antigen, the type 1 helper T cells (1) be-
come activated, secrete cytokines and cell surface molecules, 
which contribute to macrophage activation and potentiation 
of the inammatory response; c. PMN release superoxide and 
mediators that at the blood–vessel wall interface amplify re-
cruitment of inammatory cells and within the plaque con-
tribute to its vulnerability. 
Stage IV. Fibrous plaque formation: inammatory cells send 
molecular messages that govern the plaque development, in-
cluding the clonal accumulation of SMC from the media to 
the intima or from other sources (circulating bone marrow 
cells and vascular progenitor cells from artery adventitia). 
Migrated SMC switch to a secretory phenotype synthesising a 
hyperplasic basal lamina and matrix. 
Stage V. Calci!ed atherosclerotic !bro-lipid plaque: forma-
tion of a lipid rich necrotic core encapsulated by !brous tissue. 
Excess extracellular unesteri!ed cholesterol nucleates into cy-
totoxic crystals; plaque evolves to complicated atheroma. 
Stage VI. Complicated plaque: rupture, thrombosis. EC 
covering the !brous cap become thin and loaded with lipid 
droplets (EC- derived foam cells) and are prone to rupture. 
Macrophages in!ltrate the !brous cap and secrete inamma-
tory cytokines and MMPs. SMC decrease collagen synthesis. 
Mast cells secrete tryptase and chymase that assist in plaque 
destabilization and atherothrombosis. All the cells (resident 
or emigrated), every chemokine, cytokine, MMP and vasa 
vasorum (that contribute to plaque formation) are targets for 
atherosclerosis therapy. 
Targeted suppression of pro-inammatory mediators in 
adipocytes may cut the vicious connection between adipose 
tissue-obesity-inammation and atherosclerosis and help to 
prevent or retard plaque development. 
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MITOCHONDRIAL DYNAMICS: NOVEL PERFORMANCE  
IN DIABETIC MYOCARDIUM
Doina Popov
Institute of Cellular Biology and Pathology “N. Simionescu” of the Romanian Academy
Nowadays we witness a revitalization of research on mam-
malian mitochondria, along with disclosure of a plethora of 
novel functions of these organelles, including their key role 
in cellular survival and death. Mitochondria are abundant 
within cardiomyocytes occupying at least 30% of cellular vol-
ume and providing energy (ATP) for ecient contraction of 
the heart; any modication of membrane potential, of perme-
ability transition pores opening, of mtDNA structure, or the 
aberrant interactions with nucleus, intracellular lipid deposits, 
or sarcoplasmic reticulum will generate a diminished bioen-
ergetic reserve associated with impairment of heart contrac-
tility. e discussion links the electron microscopy evidence 
on mitochondrial dynamics within diabetic le ventricular 
coronary endothelium and cardiomyocytes to the newly iden-
tied molecules/mechanisms beyond it. e issues examined 
are: (i) the active bidirectional redox communication between 
endothelial cells and cardiomyocytes in diabetic myocardium, 
(ii) the intracellular events associated with mitochondrial 
dynamics, such as the fusion of healthy mitochondria with 
dysfunctional ones aiming preservation of cellular energetic 
potential, the “quality controller” role of mitochondria con-
sisting in removal of decient fragments (by ssion) and their 
elimination via a specic form of autophagy (mitophagy), the 
inter-mitochondrial exchange of membrane and matrix pro-
teins (by “kissing” and “nanotunneling”), (iii) the “retrograde 
signaling pathway” from mitochondria to the cytosol and the 
mitochondrial cross talks with nucleus, lipid droplets, and sar-
coplasmic reticulum, and (iv) a perspective of mitochondrial 
medicine in diabesity, i.e. diabetes linked to obesity. Modula-
tion of mitochondrial dynamics to prevent or treat diabesity 




METABOLIC SYNDROME: A CAUSE OR A CONSEQUENCE  
OF NONALCOHOLIC FATTY LIVER DISEASE?
Maria Mota
University of Medicine and Pharmacy Craiova, Diabetes Department, Craiova Romania
e metabolic syndrome (MetS) is an independent risk fac-
tor for nonalcoholic fatty liver disease (NAFLD). Moreover, 
NAFLD is associated with a high risk of severe liver brosis. 
e prevalence of the MetS increases with increasing BMI, 
from 18% in normal-weight NAFLD subjects to 67% in obese 
subjects. MetS is quite common in NAFLD patients; they 
are strongly associated, but it remains unknown whether 
NAFLD is a cause or eect of MetS; NAFLD predicts type 2 
diabetes and cardiovascular disease (CVD); it is important 
to identify this subset of NAFLD patients with MetS because 
they frequently have more advanced histology and also have 
a heightened risk of CVD. Nonalcoholic fatty liver disease is 
the most common liver disorder; it is an important cause of 
liver-related morbidity and mortality; NAFLD covers a range 
from simple steatosis (NAFL) to nonalcoholic steatohepatitis 
(NASH); NASH may progress to cirrhosis and end stage liver 
disease; NAFLD is the most common cause of hepatocellular 
carcinoma; NAFLD occurs in 9% of overweight patients and 
21-33% of those with morbid obesity. Ultrasonographic sur-
veys of the general population indicate the presence of fatty 
liver in 16-25% of adults in the United States. Metabolic syn-
drome is an important risk factor for CVD, as well as all-cause 
mortality; because of the close association between the MetS 
and NAFLD, there has been great interest in determining the 
actual cardiovascular risk in patients with NAFLD. NHANES 
study reported that persons with elevated serum ALT levels in 
the absence of viral hepatitis or excessive alcohol consump-
tion had an increased CVD risk. Some atherogenic mecha-
nisms related to NAFLD contributed to the excess CVD risk 
beyond what can be explained by the MetS. NAFLD is now 
considered a chronic inammatory condition and thus adds 
further atherogenic stimuli to the already high oxidative and 
proinammatory status conferred by the MetS. 
Metabolic syndrome in Romania, PREDATORR Study 
(2014): the prevalence of MetS in adult population of Romania 
(20-79 years) is 38,44% (more than six millions adult subjects).
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METABOLIC SURGERY’S EFFECTS ON END ORGAN DAMAGE
Cătălin Copăescu
Ponderas Hospital, Bucharest, Romania
During the last over 60 years, surgery has demonstrated to 
be very e ective treatment for weight loss and glycemic con-
trol. The different names associated with this selected cat-
egory of surgical procedures - weight loss surgery (WLS), 
obesity surgery, bariatric  (BS) or metabolic surgery (MS) 
- were expressing the level of understanding, using and fo-
cusing its effects for the patients’ morbidities control. Today, 
MS has proven its long term success in contrast to conserva-
tive treatment options and this is well documented in terms 
of weight loss, improvement or disappearance of comorbid 
diseases and even in gain in quantity of life. Moreover, the 
introduction of laparoscopy, of Bariatric Surgery Programs 
and Centers of Excellence (COEs): decreased the periop-
erative morbidity and the postoperative evolution is sub-
stantially improved. The IFSO –EC COEs Register (2015) 
demonstrates a very low peroperative surgical risk: Per-op-
erative complications (1.09%) 238/21.838; post-operative 
complications (2.54%) 546/21.506 Post-operative mor-
tality Late mortality (>30 
post-op days) 13/21.838 (0.06%). In Ponderas Hospital 
COE, the postoperative mortality was nil (0/5274). Dem-
the most Associations of Diabetes as a surgical options for 
adults with BMI > 35 kg/m2 and type 2 diabetes, especially 
pharmacologic therapy. As a next step MS focuses to pre-
vention /remission or control of the morbid consequences 
of obesity/T2DM In this paper is presented the evidence on 
the e cacy of MS/BS on prevention, delay, or even reversal 
of end-organ damage for: cardiovascular disease, diabetic 
kidney disease, diabetic retinopathy, NAFLD, reproductive 
-
cies. Currently BS/MS remains the only treatment offering 
predictable, long term effective weight loss and therefore 
will play a key role in minimizing, stabilizing and/or im-
proving end organ damage in obesity.
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PARTICULARITIES IN APPROACHING THE HYPERTENSIVE PATIENT 
WITH OBESITY
Maria Dorobanţu 
“Carol Davila“ University of Medicine and Pharmacy, Clinical Emergency Hospital Bucharest, 
Cardiology Department, Bucharest Romania
e hypertension-obesity association is frequently encoun-
tered in daily clinical practice, more than 60% of hypertensive 
patients being obese and requiring a special approach. Obe-
sity can impose some diculties in dening the presence and 
control of elevated blood pressure values (stressing the need 
of using adequate cus when measuring blood pressure), and 
may be a cause of resistance to antihypertensive treatment. 
In Romania, according to SEPHAR II data, the prevalence of 
obesity among hypertensive patients vary depending on the 
method used to dene obesity from 42.5% (by body mass in-
dex, BMI) up to 60.7% (by waist circumference). e most 
commonly used index for dening obesity is BMI, which is 
expressed as body weight (kg) to height (m2) ratio. At popu-
lation level, higher BMI values are associated with a greater 
prevalence of co morbidities such as type 2 diabetes and car-
diovascular disease. However, in clinical practice, equally 
obese individuals may or may not be characterized by the ex-
pected co morbidities of obesity. Other method used in daily 
practice is the measurement of subcutaneous fat by skin fold 
calipers. Both methods enable us to evaluate the total body fat. 
Visceral obesity (or abdominal obesity) which can be dened 
by waist circumference > 102 cm in males and > 88 cm in fe-
males (according to the United States National Cholesterol 
Education Program’s Adult Treatment Рanel III), or measured 
by computer tomography is now recognized as an Indepen-
dent Predictor of All-Cause Mortality. e ethiopatogenic 
link between obesity and hypertension relies on that fact that 
adipose tissue is an important endocrine organ and a site of 
production for inammatory cytokines (such as interleukin-6 
and tumor necrosis factor-α) and a potentially protective cy-
tokine (such as adiponectin, which is reduced in visceral obe-
sity). Leading to  renin-angiotensin system (RAS) stimulation, 
sodium reabsorption, insulin resistance, endothelial dysfunc-
tion and sympathetic nervous system (SNS) activation, obe-
sity can trigger the increase in blood pressure values. Also by 
favoring obstructive sleep apnea (OSA), obesity may also lead 
not only to hypertension but also to resistance to antihyper-
tensive treatment if not addressed properly by therapy. It be-
comes clear that treatment approach of hypertensive patients 
with obesity must be exhaustive. First of all weight loss must 
be the Primary treatment goal as it may improve not only 
blood pressure (each 1 kg body weight reduction, decreases 
blood pressure by 1.05/0.92 mmHg), but also the metabolic 
components and delay diabetes onset. is may be achieved 
by reduced-fat and reduced-carbohydrate hypocaloric diets 
and by physical exercise and only in restricted cases by use of 
weight loss drugs (orlistat). In patients with morbid obesity, 
bariatric surgery remains the optimal way to achieve proper 
weight loss. Regarding antihypertensive drugs, mono-therapy 
is seldom sucient to control blood pressure. Trying to iden-
tify reasonable rst choices drugs, “…as MS can be consid-
ered a pre-diabetic state, antihypertensive agents potentially 
improving or at least not worsening insulin sensitivity such as 
RAS blockers and calcium antagonists, should be considered 
as the preferred drugs”. Especially in these types of patients 
the doctors must consider metabolic side-eects of antihyper-
tensive drugs (especially for beta-blockers and thiazides). In 
case of resistance to treatment, central sympatholytic drugs 
are another treatment option (obesity being characterized by 
increased SNS tone). Also active screening for OSA in these 
patients is mandatory and if detected OSA treatment strate-
gies - upper airways surgery, mandible protruding devices, 
and continuous positive airway pressure must be applied 
alongside antihypertensive treatment, as eective treatment of 
OSA, may reduce cardiometabolic risks. Likewise, renal sym-
pathetic denervation could substantially reduced blood pres-
sure in patients with real treatment-resistant hypertension 
and may also improve glucose metabolism.
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RISK OF LIVER CANCER IN NONALCOHOLIC STEATOHEPATATIS 
Mihai Voiculescu
Fundeni Clinical Institute, Centre of Internal Medicine, Bucharest, Romania
Hepatocellular carcinoma (HCC) is the only digestive can-
cer with a continuous increase of incidence, prevalence and 
mortality. e mortality to HCC has increased by more than 
50% in the last two decades and remains as one of the cancer 
with the highest mortality ratio to incidence (0.95). So, HCC 
is now the second most frequent cause of death from all diges-
tive cancers, aer pancreatic cancer. Also the lethality of HCC 
is highs (0.9), very few new cases survive over one year.
Variables OR (95% CI) p value
PNPLA3 736409 genotype 2.26 (1.23-4.14) 0.0082
Age 1.24(1.17-1.32) <0.0001




Table 1. Multivariate analysis of the eect of PNPLA3 genotype 
on NAFLD related HCC risk (see 1).
Recent epidemiological data suggest a causal relation ship 
between NASH and HCC. Many mechanisms are involved in 
HCC pathogenesis in nonalcoholic fatty liver disease (NAFLD) 
and nonalcoholic steatohepatitis (NASH): oxidative stress, in-
!ammation and metabolic disarray, the most important risk 
factors being PNPLA3 genotype age, male, gender, diabetes 
mellitus, obesity and liver cirrhosis (Table1). Hepatocellular 
carcinoma could be present even in non-cirrhotic NAFLD 
and NASH. ere are no drugs which could prevent HCC 
in these liver diseased. Early HCC detection is performed by 
abdominal ultrasound and alpha-feto-protein every 4 month 
in the high risk populations as cirrhotic, obesity and diabetes 
patients, also older males.
1.  Liu YL, et al. Carriage of the PNPLA3 rs738409 C >G poly-
morphism confers an increased risk of non-alcoholic fatty 




THE IMPORTANCE OF A HEALTHY FOOD, WATER AND ENVIRONMENT FOR THE 
DEVELOPMENT AND PERFORMANCE OF THE HUMAN BRAIN
Alexandru V. Ciurea1, A. Mohan2, and H. Moisa1
1Carol Davila University School of Medicine, Department of Neurosurgery, Bucharest, Romania. Sanador 
Medical Center, Department of Neurosurgery, Bucharest, Romania and 2University of Oradea, Faculty of 
Medicine, Department of Neurosurgery, Oradea, Romania.
e authors debate the major actual problem of healthy nutri-
tion and its impact on the development of the nervous system 
referring mostly to young persons and the intrauterine period. 
e modications of the human genome through alimenta-
tion, water and environment can be in such circumstances un-
predictable and irreversible. e development of the human 
body depends mostly on genetic factors. ese in turn depend 
on a series of nutritional factors, environmental factors and 
possible nociceptive external aggressions. e maximal tera-
togenous period stretches from the 2nd week of pregnancy 
until the 30th week, with the brain being the most sensitive 
organ prone to lesions. e nervous cell is highly sensitive 
to teratogenous agents. Nutriments need to be chosen care-
fully to allow the best course of development of the organism 
and especially the nervous system. Young organisms until the 
age of 20 need to be protected from poisonous factors from 
food and the external environment. Studies from all over the 
world have demonstrated that food and water inuence the 
genotype and the fenotype in a decisive way being the source 
or vector of a various array of diseases. e consequences of 
“industrial alimentation” enriched with growth hormones and 
other alimentary additives are shown in this study together 
with the poisonous eects of alcohol consumption, tobacco, 
drugs, radiation etc. Furthermore the authors bring in dis-
cussion quantum mechanics and physics studies that aim to 
show that all human beings are interconnected and that each 
one of us has the potential to inuence his partners by what 
he thinks. At the end the authors insist upon alimentation is-
sues promoting natural food and presenting in parallel the 
risks and possible consequences of genetically modied food. 
e authors advocate against mall culture and industrial ali-
mentation while presenting the advantages gained by natural 
alimentation and the use of several well known herbal rem-
edies. Also, the authors wish to emphasize the proper hydra-
tion through natural water (unaltered industrially, chemically 
or carbonated) and the external elements which inuence the 
cerebral activity (stress, smoking, alcohol and environment). 
All these constellations must be obeyed as much as possible in 
order to obtain a proper harmonious cerebral development for 
young persons and also for the preservation of the brain activ-
ity in mature persons. Given the very large metabolic needs of 
the human brain, the healthy nutrition is a crucial factor in the 
brain development especially in the intrauterine period and 
early childhood together with the inuence of external factors 
and, intriguingly, the development of gut microbiota (1). 
1.  Goyal MS, Venkateshb S, Milbrandtd J, Gordonb JI, Raichle 
ME. Feeding the brain and nurturing the mind: Linking 
nutrition and the gut microbiota to brain development. 
Proc Nat Acad Sci USA  2015; 112: 14105–14112. DOI: 
10.1073/pnas.1511465112
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GENETIC FACTORS INVOLVED IN THE PATHOGENESIS OF HUMAN OBESITY 
Cristian Guja
National Institute of Diabetes, Nutrition and Metabolic Diseases “Prof. NC Paulescu”, Bucharest, Romania 
Obesity is one of the most common chronic diseases in hu-
man populations across the globe, the current epidemic aect-
ing over 500 million adults. Similar to other common human 
complex diseases obesity pathogenesis involves both genetic 
and environmental factors. e last include hypercaloric diet, 
sedentarism, stress and other conditions such as urbanization 
and westernized lifestyle. Considerable evidence from epi-
demiologic twin, adoption and family studies indicated that 
body weight and body fat disposition have a heritability of 
up to 70%, highlighting the importance of heredity/genet-
ics. e discovery of single gene variants associated with rare 
causes of extreme obesity in children highlighted the pivotal 
role of hormonal and neural hypothalamic networks regulat-
ing body weight. e majority of these genes were discov-
ered following studies in animal models (mice) and subse-
quently conrmed in humans. Among these are the genes for 
leptin (Lep), leptin receptor (LepR), proopiomelanocortin 
(POMC), melanocortin 4 receptor (MC4R) and prohormone 
convertase 1 (PCSK1). Some other gene variants were dis-
covered analyzing the equally rare cases with complex syn-
dromes associating obesity. Again most genes identied are 
related to central nervous system appetite centers. In con-
trast with the severe obesity cases induced by homozygous 
mutations in these genes, carriers of heterozygous mutations 
exhibit less severe obesity. In contrast with monogenic forms 
of obesity, in the common form of polygenic obesity the ge-
netic risk is inuenced by the combined eect of variation 
at numerous loci. us, the recent genome-wide association 
studies for obesity related traits such as body mass index or 
waist circumference identied more than 120 gene variants/
loci, the vast majority with a modest eect (their combined 
eect explains only a small part of BMI heritability). Many 
of these were shown to be highly expressed in the brain, 
particularly in the hypothalamus, highlighting again their 
importance in regulating food intake and, subsequently, adi-
posity. e fat tissue and obesity associated gene (FTO) on 
chromosome 16 was the rst gene convincingly proven to be 
associated with common human obesity. e fact that gene 
variants identied so far has such a poor predictive value 
for obesity, especially when compared with risk calculators 
based on clinical factors, is known as missing heritability and 
has several potential explanations. Epigenetic factors (such 
as DNA methylation and histone modication) presumably 
play an important role in the pathogenesis of human obesity. 
ey might mediate the eects of the environment on the 
risk of obesity. Further research is needed to clarify the role 
of genetic variation and epigenetic mechanisms in the devel-
opment of human obesity.
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PHARMACOLOGICAL INHIBITION OF HISTONE DEACETYLASE REDUCES 
OXIDATIVE STRESS AND INFLAMMATION IN THE AORTA OF DIABETIC MICE
Adrian Manea, Simona-Adriana Manea, Ioana Madalina Fenyo, Mihaela Loredana Antonescu, 
Monica Raicu, and Maya Simionescu
Institute of Cellular Biology and Pathology “Nicolae Simionescu” of the Romanian Academy, Bucharest, Romania
Hyperglycaemia-induced functional and structural altera-
tions of the vascular wall in diabetes are partially mediated 
by oxidative stress generated by the activated NADPH oxidase 
(Nox). Hitherto, the molecular mechanisms that accounts for 
Nox upregulation are not entirely elucidated. In this study we 
hypothesize that histone acetylation has a role in the regula-
tion of Nox and that histone deacetylase (HDAC) inhibition 
may have the potential to counteract the vascular oxidative 
stress and inammation in diabetes. Male C57BL/6J mice 
were rendered diabetic with streptozotocin. e animals were 
distributed into four experimental groups to receive vehicle or 
suberoylanilide hydroxamic acid (SAHA), a selective HDAC 
inhibitor, every other day for four weeks: (i) non-diabetic + 
vehicle, (ii) non-diabetic + SAHA, (iii) diabetic + vehicle, and 
(iv) diabetic + SAHA. Lucigenin-enhanced chemilumines-
cence assay, real-time PCR, and Western blot analysis were 
employed to investigate vascular epigenetic changes, Nox 
regulation, and the expression of pro-inammatory markers. 
Western blot analysis revealed that the HDAC1 and HDAC2 
protein expression levels were signi!cantly elevated in the aor-
ta of diabetic mice compared to non-diabetic control animals. 
Treatment of diabetic mice with SAHA greatly reduced the 
augmented Nox activity and the gene and protein expression 
of the Nox1, Nox2, and Nox4 subtypes. Pharmacological tar-
geting of HDAC generated vascular anti-inammatory activi-
ties as illustrated by the inhibitory e"ects of SAHA on inter-
cellular adhesion molecule 1, vascular cell adhesion molecule 
1, and monocyte chemoattractant protein-1 gene expression 
in the aorta of diabetic mice. In conclusion, pharmacological 
inhibition of HDAC reduced Nox expression and the ensu-
ing reactive oxygen species formation in the aorta of diabetic 
mice. ese data indicate the existence of a new epigenetic 
mechanism whereby changes in chromatin conformation 
leads to Nox upregulation and inammation in vascular cells 
in diabetes. 
is work supported by grants of the Romanian Na-
tional Authority for Scienti!c Research (PN-II-ID-
PCE-2011-3-0548, PN-II-RU-TE-2011-3-0142). Simona-
Adriana Manea acknowledges the support of the strategic 
grant POSDRU/159/1.5/S/133391-!nanced by the European 
Social Found within the Sectoral Operational Program Hu-
man Resources Development 2007 – 2013.
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GLUCOCORTICOIDS UPREGULATE APOLIPOPROTEIN E GENE EXPRESSION IN A 
MACROPHAGE-SPECIFIC MANNER
Violeta G. Trusca1, Elena V. Fuior1, Madalina I. Fenyo1, Dimitris Kardassis2, and Anca V. Gafencu1
1Department of Genomics, Transcriptomics and Molecular Therapies, Institute of Cellular Biology and 
Pathology, “Nicolae Simionescu” of the Romanian Academy, Bucharest, Romania and 2Department of Basic 
Sciences, University of Crete Medical School and Institute of Molecular Biology and Biotechnology, Foundation 
for Research and Technology of Hellas, Heraklion, Crete, Greece
Apolipoprotein E (apoE), a glycoprotein involved in the li-
poprotein metabolism, is synthesized by the liver and other 
peripheral sources. Macrophage-derived apoE plays an ath-
eroprotective role, while its overexpression in the liver causes 
hypertriglyceridemia. e aim of our work was to investigate 
the glucocorticoid induced cell-specic mechanism of apoE 
gene regulation. ApoE gene expression in mouse peritoneal 
macrophages, RAW 267.4 and HepG2 cells treated with the 
ligand (dexamethasone) or antagonist (mifepristone) of glu-
cocorticoid receptor (GR) was tested by Real-Time PCR us-
ing TaqMan probes. e eect of short-term dexamethasone 
treatment on apoE gene expression in macrophages and liver 
of C57BL/6J mice was also evaluated. e capacity of ligand-
activated GRs to enhance the apoE promoter activity was as-
sessed by transient transfections using plasmids encoding the 
apoE proximal promoter and GRα expression vectors, in the 
presence of dexamethasone. GR binding on the apoE promot-
er was tested by DNA pull-down assays and chromatin im-
munoprecipitation experiments. Real-Time PCR experiments 
showed that dexamethasone treatment induced a 5-6 fold 
increase in apoE mRNA levels in RAW 264.7 macrophages 
and mouse peritoneal macrophages, but not in hepatocytes. 
Mifepristone treatment resulted in a signicant reduction of 
apoE expression in macrophages. One week dexamethasone 
administration to C57BL/6J mice increased apoE mRNA lev-
els in macrophages, but not in liver. Dexamethasone-activated 
GRs specically increased the activity of apoE promoter in 
macrophages. DNA pull-down assays showed that GRs bind 
to -115/-65 region of the apoE promoter and chromatin im-
munoprecipitation indicated that GRs are recruited to the 
apoE promoter following dexamethasone treatment of cells. 
Taken together, our data revealed a dierential eect of glu-
cocorticoids on apoE gene expression, in macrophages and 
hepatocytes. Despite that GR binding site (located in the re-
gion -115/-65 of the apoE promoter) is functional in both 
cell type analyzed, the glucocorticoids regulate the apoE gene 
expression in a macrophage-specic manner. ese data may 
contribute to the identication of specic drugs increasing the 
apoE level selectively in macrophages, to stimulate the choles-
terol e!ux from the atherosclerotic plaque. 
is work was supported by a grant of the Romanian 
National Authority for Scientic Research (CNCS – UE-
FISCDI), PN-II-ID-PCE-2011-3-0591 (awarded to AG), by a 
grant from the Hellenic Ministry of Education (THALIS MIS 
377286, awarded to DK) and by the Romanian Academy. M. 
Fenyo and V. Trusca acknowledge the support of the strategic 
grant POSDRU/159/1.5/S/133391-nanced by the European 
Social Fund within the Sectoral Operational Program Human 
Resources Development 2007 – 2013.
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IMPROVEMENT OF THE METABOLIC PROFILE AND PREVENTING 
ATHEROSCLEROSIS IN OBESE CHILDREN BY USING SOME SUPPLEMENTS
Laura Popescu1, Daniela Elena Casariu2, Bogdana Virgolici1, Daniela Lixandru1, Horia Marius 
Virgolici1, Olivia Timnea2, Leon Zagrean1, Dumitru Oraseanu1, and Maria Mohora1 
1University of Medicine and Pharmacy „Carol Davila”, Bucharest, Romania and 2Medical O!ces,  
Bucharest, Romania
It was demonstrated that omega-3 fatty acids supplements and 
sea-buckthorn (Hippophae rhamnoides) pulp oil obtained by 
cold pressing have antiin!ammatory e"ects and improve the 
lipid pro#le in obese adults. Less studies were done in child-
hood obesity. $e aim of this study is to investigate the bene#-
cial e"ects of the supplements in obese children. In our studies 
done in 59 obese children (10-16 years old) versus 30 healthy 
controls we measured blood parameters before and a%er three 
months of treatment either with 323 mg/day of omega-3 fatty 
acids (EPA, DHA) associated with vitamin A 200 µg, vitamin 
D 1.25 µg, vitamin E 2.5 mg and vitamin C 30 mg or with 800 
mg/day Sea-buckthorn pulp oil. Spectrophotometric and ELI-
SA methods were used. Usual plasma variables (glycaemia, 
creatininemia), antropometric parameters, plasma triglycer-
ides, in!ammatory and oxidative stress markers, adipokines, 
plasma minerals, insulin resistance markers, anti#brinolitic 
factor PAI-1 and preatherosclerotic marker (carotid intima 
media thickness) markers were improved signi#cantly a%er 
treatment. In conclusion, omega-3 fatty acids and sea-buck-
thorn pulp oil supplements are highly recommended in obese 
insulinoresistent children.
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ADIPOKINES PROFILE AND CNR1 POLYMORPHISMS IN METABOLICALLY 
UNHEALTHY LEAN AND METABOLICALLY HEALTHY OBESITY PHENOTYPES
Simona G. Popa1, Maria Mota1, Adina Mitrea2, Mihai Ioana3, Camelia Stanciulescu4,  
and Cornelia Zetu5
1Diabetes, Nutrition and Metabolic Diseases, University of Medicine and Pharmacy, Craiova, 
Romania, 2Diabetes, Nutrition and Metabolic Diseases, Emergency Clinical Hospital, Craiova, 
Romania, 3Molecular Genetics, University of Medicine and Pharmacy, Craiova, Romania,4Biochemistry, 
University of Medicine and Pharmacy, Craiova, Romania, and 5“N.C. Paulescu” National Institute of Diabetes, 
Nutrition and Metabolic Diseases, Bucharest, Romania
Metabolically healthy obese and metabolically unhealthy lean 
are two atypical metabolic phenotypes whose characteristics 
and prognosis are a subject of extensive scientic debate. e 
endocannabinoid system may contribute to the association of 
fat accumulation with metabolic disorders. e aim was to as-
sess the prevalence of dierent metabolic phenotype and to an-
alyze the adipokines prole, insulin resistance and ve single 
nucleotide polymorphisms of endocannabinoid type 1 recep-
tor (CNR1) in metabolically healthy obese and metabolically 
unhealthy lean phenotypes. We performed a cross-sectional 
analysis in a random sample of 507 individuals (52.9±14 years, 
47.1% male) which were classied as metabolically healthy 
lean (MHL) or overweight/obese (MHO) and metabolically 
unhealthy lean (MUHL) or overweight/obese (MUHO), 
based on the body mass index (BMI) and presence of meta-
bolic syndrome. Single nucleotide polymorphisms of CNR1 
(rs12720071, rs806368, rs1049353, rs806381, rs754387) were 
genotyped. e frequency of MHO, MUHL and MUHO phe-
notypes was 16.2%, 6.9% and, respectively 58.6% among all 
participants. MHO exhibited signicantly lower leptin levels 
[MHO: 11.7 ng/ml (interquartile range 3.8-17.4) vs MUHO: 
14.9 ng/ml (interquartile range 6.7-24.6) versus MHL: 4 ng/
ml (interquartile range 1.5-15.5)], insulin levels [MHO: 9.4 
μUI/ml (interquartile range 6.8-12.2) vs MUHO: 11.6 μUI/
ml (interquartile range 8.3-15.7) versus MHL: 6.6 μUI/ml 
(interquartile range 3.9-10.3)] and HOMA-IR [MHO: 2.6 (in-
terquartile range 1.7-3.4) vs MUHO: 3.4 (interquartile range 
2.4-4.7) versus MHL: 1.6 (interquartile range 0.9-2.6)] than 
MUHO participants, but signicantly higher than MHL par-
ticipants. MUHL participants had similar adipokines prole 
but signicantly higher HOMA-IR [2.2 (interquartile range 
1.5-4)] than MHL. Leptinemia, insulinemia and HOMA-IR 
were signicantly lower in MUHL than in MUHO subjects. 
Expression of CNR1 genes showed a similar alteration pat-
tern in all metabolic phenotypes. Multivariate logistic re-
gression analysis revealed age, HOMA-IR [OR 24.3 (CI 6.2-
95.2), p < 0.001], adiponectin [OR 0.9 (CI 0.9-0.99), p = 0.04] 
and insulin [OR 0.5 (CI 0.3-0.6), p < 0.001] as independent 
predictors of MUHL phenotype. HOMA-IR [OR 12.3 (CI 3.2-
47.1),  p  <  0.001], insulin [OR 0.6 (CI 0.4-0.8),  p  =  0.0012], 
leptin [OR 1.1 (CI 1.1-1.2), p = 0.02] and adiponectin [OR 0.9 
(CI 0.9-0.98), p = 0.01] were independent predictors of MHO 
phenotype. e mutant G allele (GG+AG) of rs12720071 re-
duces the odds of having MHO phenotype by approximately 
80% (p = 0.02). MHL was considered the reference category 
in regression analysis. e current study provides evidence 
that MHO subjects had more impaired adipokines prole and 
were less insulin sensitive than MHL subjects, thus the MHO 
concept should be applied with caution. Insulin resistance and 
adverse adipokines prole were less frequent in MHO and 
MUHL than in MUHO subjects. Only rs12720071 has been 
identied as a modulator of the MHO phenotype. 




THE SYNERGY BETWEEN ADIPOSE TISSUE GRAFT, ADSC, LASER AND PRP  
IN THE CONTEXT OF REGENERATIVE PLASTIC SURGERY
Dana Jianu, Maria Filipescu, Stefan Jianu, Oltjon Cobani, Andreea Nita, and Marian Turbatu
PROESTETICA HOSPITAL – Research Center in Regenerative Medicine and Surgery of Romanian Academy  
of Medical Sciences, Bucharest, Romania
Surgical techniques based on transfer of autologous fat, ad-
ipose-derived stem cells (ADSC), ablative surgical LASERS 
and PRP have among other eects a strong biostimulative tis-
sue regenerative outcome. ey are becoming part of newly 
appeared plastic regenerative surgery (PRS). Each component 
of our approach has its own advantages when used alone, but 
when used in combination there are clinical and histological 
evidences that the synergistic eect gives an empowered re-
sult which is superior to each of individual component result. 
is is due to the stem cells’ and other cells’ activating and 
healing potential under the stimulative and complementary 
eect of LASER and PRP. Nowadays, in our practice, we are 
currently oering treatments of PRS. By the time we rened 
and enriched our techniques and equipment. Since 2008, in 
Plastic Surgery Department of ProEstetica Medical Center, 
over 300 patients underwent single at the beginning and then 
combined regenerative closed surgery based on the following 
methods introduced gradually: 1. Fat transplant (microgras) 
and nanogras since 2013. When necessary, fat removal by 
ne lipoaspiration was done. 2. LASER assisted lipolysis (LAL) 
with optical ber (DIODE LASER λ = 980 nm) since 2008. 
Fractional CO2 LASER (λ = 10600 nm) for resurfacing and 
fat gra stimulation since 2008. 3. PRP treatment (injections 
and spreading) since 2012. 4. Additional ADSC standardized 
enzymatic digestion from lipoaspirate since 2013. Autologous 
fat transplant proved to be an important regenerative clinical 
application due to is composition of progenitor (stem) cells 
and other regenerative factors. From clinical experience and 
research ndings we arrived to the following conclusions: 
1. e ADSC lead to better results when combined with fatty 
tissue (enriched AFT). 2. e fat gra has a better survival rate 
and less complications when is enriched with ADSC (ex: in 
breast correction). 3. Additional LASER treatments, especially 
fractional CO2 LASER application is optimizing the regenera-
tive activity of ADSC and autologous fat gra. Taking in con-
sideration the clinical observations we started to learn more 
through research about optimization eect over fat and ADSC 
when LASER exposure was performed. 4. Growth factors and 
cytokines administrated simultaneously with ADSC and AFT 
are also optimizing factors in PRP. 
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OXIDIZED LDL INDUCE THE EXPRESSION OF PRO-INFLAMMATORY MOLECULES 
IN LIPID-LOADED MACROPHAGES
Gabriela M. Sanda1, Mariana Deleanu1,2, Anca V. Sima1, and Maya Simionescu1
1Institute of Cellular Biology and Pathology “Nicolae Simionescu” of the Romanian Academy, Bucharest, 
Romania and 2Faculty of Biotechnology, University of Agronomical Sciences and Veterinary Medicine, 
Bucharest, Romania
Oxidation of plasma proteins and lipids, including low den-
sity lipoproteins (LDL), contributes to accelerated atheroscle-
rosis. e oxidative processes alter the proper functioning of 
the endoplasmic reticulum (ER), the site of protein and lipid 
synthesis, resulting in ER stress which activates the inamma-
tory pathways in macrophages. e aim of this study was to 
evaluate whether exposure of human macrophages in culture 
to oxidized LDL (oxLDL) stimulates the secretion of pro-in-
ammatory molecules, such as C-reactive protein (CRP) and 
matrix metalloproteinase-9 (MMP-9) and if oxLDL-induced 
ER stress and oxidative stress determine the secretion of CRP 
and MMP-9 from lipid-loaded macrophages. Oxidized LDL 
were prepared by incubation of native LDL (nLDL) with 
10µM CuSO
4 
at 37°C for 24 h, dialysed extensively, kept under 
sterile conditions and used within 2 weeks. Cultured THP-1 
macrophages were incubated with oxLDL, in the presence or 
absence of inhibitors of ER stress (sodium phenylbutyrate, 
PBA) or oxidative stress (N-acetyl cysteine, NAC, and apocy-
nin, a NADPH oxidase inhibitor). e following parameters 
were determined: (i) free cholesterol (FC), total cholesterol 
(TC), 7-ketocholesterol (7-KC) by gas chromatography-mass 
spectrometry GC/MS/MS; (ii) ER stress markers, NADPH 
oxidase activity and reactive oxygen species (ROS) produc-
tion by Western blot, chemiluminescence and spectrouori-
metric techniques; (iii) secreted CRP and MMP-9 by West-
ern blot, and (iv) secreted MMP-9 activity by zymography. 
Incubation of THP-1 macrophages with oxLDL versus nLDL 
induced: (a) intracellular accumulation of free and esteri!ed 
7-KC; (b) ER stress, by the activation of eukaryotic initiation 
factor-2 α (eIF2α) and by the up-regulation of C/EBP homolo-
gous protein (CHOP); (c) increase of NADPH oxidase activ-
ity and ROS production; (d) increased CRP gene expression 
and protein secretion, and (e) increased MMP-9 gene expres-
sion, protein secretion and enzymatic activity. Furthermore, 
the experiments demonstrated that oxLDL-induced CRP gene 
expression and protein secretion were reduced by the inhibi-
tors of oxidative stress, while oxLDL-induced MMP-9 gene 
expression, protein secretion and enzymatic activity were 
diminished by the inhibition of the ER or oxidative stress. 
Oxidized LDL have notable e#ects on human macrophages: 
they induce CRP secretion via a mechanism that involves the 
oxidative stress, and enhance and modulate MMP-9 secretion 
and enzymatic activity by the activation of both ER and oxida-
tive stress.
is work was supported by the Romanian Academy and 
by the PN-II-PT-PCCA-2011-3.1-0184 project. Gabriela 
M. Sanda acknowledges the support of the strategic grant 
POSDRU/159/1.5/S/133391 !nanced by the European Social 
Found within the Sectoral Operational Program Human Re-
sources Development 2007 – 2013. 
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NONALCOHOLIC FATTY LIVER DISEASE: A NEW CARDIOVASCULAR RISK FACTOR?
Andreea Motoc and Mihai Voiculescu 
University Emergency Hospital, Department of Cardiology, Bucharest, Romania and Fundeni Clinical Institute, 
Centre of Internal Medicine, Bucharest, Romania
Nonalcoholic fatty liver disease (NAFLD) is the most preva-
lent liver disease in developed countries, with an incidence 
of 30-35% in the general population. Nonalcoholic fatty liver 
disease is not only associated with liver-related morbidity and 
mortality, but also with an increased risk of cardiovascular dis-
ease (CVD), abnormalities of cardiac function and structure, 
valvular heart disease and arrhythmias. Moreover, there is a 
large body of clinical and epidemiological evidence support-
ing the concept that NAFLD is strongly associated with major 
cardiovascular risk factors, including type 2 diabetes mellitus, 
obesity, dyslipidemia, hypertension and insulin resistance. 
e mechanisms linking NAFLD with CVD are not fully un-
derstood yet, but recent studies show that NAFLD, especially 
in its more severe forms, exacerbates systemic/hepatic insulin 
resistance, causes atherogenic dyslipidemia and releases a va-
riety of pro-inammatory, pro-coagulant and pro-brogenic 
mediators that may play important roles in the pathophysiol-
ogy of cardiac complications. ese ndings suggest that the 
clinical impact of NAFLD on CVD risk deserves particular 
attention and patients with NAFLD may benet from more 
intensive surveillance and early treatment to decrease the risk 
of CVD and other cardiac complications. Although the mech-
anisms underlying the association between NAFLD and CVD 
are not fully understood and the prognostic value of NAFDL 
in CVD risk stratication has yet to be determined, attention 
must be paid to this association, given that many patients with 
NAFLD, especially those with nonalcoholic steatohepatitis 
(NASH) will develop major CVD events and die prior to the 
development of advanced liver disease. In conclusion, far from 
being a benign and “paraphysiological” condition, NAFLD 
should be viewed as a complex and multi-faceted disease of-
ten calling for multi-disciplinary intervention, a collaboration 
between cardiologists and hepatologists being essential for the 
treatment and management of these patients. 
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KIDNEY IN NONALCOHOLIC FATTY LIVER DISEASE
Georgia Elena Micu
I.C. Fundeni, Hephrology Clinic, Bucharest, Romania
Nonalcoholic fatty liver disease (NAFLD) is the most com-
mon cause of chronic liver disease in Western countries 
that is predicted to become also the most frequent indica-
tion for liver transplantation by 2030. e term „nonalco-
holic fatty liver disease” was coined by gastroenterologists 
almost 20 years ago to dene a spectrum of progressive liver 
disease that encompasses simple steatosis and nonalcoholic 
steatohepatitis (NASH), which is characterized by the pres-
ence of steatosis, necroinammation, and/or brosis, and 
ultimately cirrhosis. e same entity was also well known 
to diabetologists and regarded as an epiphenomenon of the 
metabolic syndrome. In recent years, this perspective has 
completely been changed by the combined research eorts 
of both gastroenterologists and endocrinologists, determin-
ing that NAFLD itself can lead to an increased risk of de-
veloping metabolic syndrome and its complications beyond 
established predictors. e primary focus of this review will 
be on the association between NAFLD and a spectrum of 
extrahepatic diseases that were traditionally linked to meta-
bolic syndrome such as type 2 diabetes mellitus, cardiovas-
cular disease, chronic kidney disease, and cancers. e top 
three leading causes of death in patients with NAFLD in de-
scending order are cardiovascular disease, cancer, and liver 
disease. It is clear now that the increased risk of metabolic 
and macro- and microvascular complications in NAFLD 
stems from the associated features of metabolic syndrome. 
However, NAFLD itself may contribute to the spectrum 
of risk factors associated with insulin resistance. Hepatic 
lipid accumulation in NAFLD impairs hepatic glucose and 
lipid metabolism further increasing the risk of type 2 dia-
betes mellitus and of cardiovascular disease, independently 
of established risk factors. e incidence, prevalence, and 
severity of these complications are proportional to the his-
tological severity of liver damage suggesting that NAFLD, 
but particularly NASH, can also contribute to the low-grade 
inammatory state through the systemic release of several 
markers of inammation, oxidative stress, and of procoagu-
lant factors. e clinical implication of these ndings is that 
patients with NAFLD require a multidisciplinary evaluation, 
with a major focus on type 2 diabetes mellitus and cardio-
vascular disease complications and may benet from more 
intensive surveillance and early treatment interventions to 
decrease the risk for cardiovascular and kidney complica-
tions. e possible link between NAFLD and chronic kidney 
disease (CKD) has recently attracted considerable scientic 
interest. Several large cross-sectional population and hos-
pital-based studies, involving both adults without diabetes 
and patients with diabetes, have shown that the prevalence 
of CKD (dened as either decreased estimated glomerular 
ltration rate (GFR) and/or overt proteinuria) is increased in 
people with NAFLD. ese studies have used either ultraso-
nography or biopsy to diagnose NAFLD and have excluded 
patients with end-stage renal disease, cirrhosis and those 
with known causes of chronic liver disease (alcohol abuse, 
viral hepatitis and use of hepatotoxic drugs in all studies and 
also hemochromatosis and autoimmune hepatitis in some 
studies). In these studies, the prevalence of CKD in patients 
with NAFLD ranged from approximately 20–55% compared 
to 5–35% in patients without NAFLD. Importantly, most of 
these studies, including those that used liver biopsy to di-
agnose NAFLD, reported that the presence and severity of 
NAFLD was associated with CKD stages, independently of 
established cardio-renal risk factors. To date, there is a pau-
city of published data regarding the risk of developing CKD 
in patients with NAFLD. Notwithstanding these limitations, 
the published prospective studies have consistently reported 
an independent association between NAFLD and increased 
risk of incident CKD with HRs for CKD that ranged from 
approximately 1.3–1.9. Very recently, in a well-conducted 
systematic review and meta-analysis (63,902 participants, 20 
cross-sectional and 13 longitudinal studies included), Musso 
et al (1) conrmed that NAFLD as diagnosed by histology, 
imaging or liver enzyme elevation was signicantly associ-
ated with an increased risk of prevalent (OR 2.12, 95% CI 
1.69–2.66) and incident CKD (HR 1.79, 95% CI 1.65–1.95). 
Additionally, NASH was associated with a higher prevalence 
(OR 2.53, 95% CI 1.58–4.05) and incidence (HR 2.12, 95% 
CI 1.42–3.17) of CKD than simple steatosis. However, fur-
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ther longer prospective studies in larger cohorts of patients 
with biopsy-proven NAFLD are needed to conrm these 
ndings, and to determine whether improvement in NAFLD 
(or future treatments for NAFLD) ultimately will prevent or 
delay the development and progression of CKD. Moreover, 
because CKD has many potential causes, it also will be of 
great interest to characterize the renal injury manifestations 
associated with NAFLD and clarify, in the future, whether 
NAFLD may selectively contribute to the pathogenesis of 
dierent types of kidney disease (1-3).
1. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias 
S, Hamaguchi M, et al. Association of non-alcoholic fatty 
liver disease with chronic kidney disease: a systematic re-
view and meta-analysis. PLoS Med 2014; 11:e1001680.
2. Targher G, Mantovani A, Pichiri I, Mingolla L, Cavalieri 
V, Mantovani W, et al. Nonalcoholic fatty liver disease is 
independently associated with an increased incidence of 
chronic kidney disease in patients with type 1 diabetes. 
Diabetes Care 2014; 37:1729-1736. 
3. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahe-
patic complications of nonalcoholic fatty liver disease. 
Hepatology 2014; 59:1174-1197.
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NEW TOOLS FOR PREDICTION AND ASSESSMENT OF OBESITY IN CHILDREN
Raluca Ioana Stefan-van Staden and Livia Alexandra Gugoasa
Laboratory of Electrochemistry and PATLAB Bucharest, National Institute of Research for Electrochemistry and 
Condensed Matter, Bucharest, Romania
Obesity in children became a public health problem. e role 
of adipose tissue is not only to store and metabolize lipids, 
but to function as an endocrine organ by releasing adipokines 
involved in the regulation of inammation (e.g. interleukins, 
leptin, adiponectin), coagulation (plasminogen activator in-
hibitor-1, PAI-1), feeding behavior (leptin) and insulin resis-
tance (TNF-α). e adipokine levels rise with an increase in 
adipose tissue and adipocyte volume and can aect the health 
on long term. erefore, it was important to develop new tools 
for assessing these substances as well as of other ones like E2, 
T2, DHT and bisphenol A in childrens’ saliva and whole blood. 
Stochastic sensors based on carbon and textile matrices and 
nanostructured materials were proposed as new tools for the 
screening of saliva and whole blood. No sampling was need-
ed for either saliva or whole blood for detection and quanti-
!cation of E2, T2, DHT, bisphenol A, TNF-α, IL-6, MCP-1, 
PAI-1, and leptin. e sensors were introduced in 30-50µL of 
sample, and these markers were identi!ed accordingly with 
their signature from the diagrams. A#er their identi!cation, 
they were quanti!ed using the calibration equations. e new 
tools designed based on stochastic sensors were able to detect 
and quantify E2, T2, DHT, bisphenol A, TNF-α, IL-6, MCP-1, 
PAI-1, and leptin, at levels between fg/mL to ng/mL with high 
sensitivity and selectivity. e range of utilization made pos-
sible the analysis of these substances in children’s saliva and 
whole blood, favorizing the prediction and assessment of the 
obesity in children, but also identifying the risk factors for as-
sociated illnesses. e new tools can detect fast and reliable 
the hormones, bisphenol A, citokines and adipokines in saliva 
and whole blood samples of children, being good alternatives 
for accredited methods like ELISA. For the assay of many of 
these substances, there is no alternative in clinical analysis for 
samples like, e.g., saliva samples, due to the low levels of these 
substances in the biological uids of children.
is work was supported by UEFISCDI PNII Program 
Ideas 2011-2014, Contract nr. 123/05.10.2011 and the Europe-
an Community’s Seventh Framework Programme [FP7/2007-
2013] under grant agreement OBELIX n° 227391.
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INCREASED METABOLIC RESPONSE OF SUBCUTANEOUS ADIPOSE TISSUE-
DERIVED STROMAL CELLS AFTER IN VITRO EXPOSURE TO SERUM FROM 
OBESE SUBJECTS
Alina Constantin1, Miruna Nemecz1, Madalina Dumitrescu1, Gabriela Tanko1, Doina Popov1, 
Dana Jianu2, Cătălin Copăescu3, and Maya Simionescu1
1Institute of Cellular Biology and Pathology, “Nicolae Simionescu”, Bucharest, Romania,
 2PROESTETICA Medical Center, Bucharest, Romania, and 3PONDERAS Hospital, Bucharest, Romania
Subcutaneous adipose tissue is an important source of multi-
potent stem cells and a key player for the pathophysiology of 
obesity. These two features of adipose tissue are interconnect-
cells in regenerative therapies, their involvement in adipose 
tissue dysfunction in obesity and related metabolic disorders 
has not been entirely uncovered. The aim of this study was 
to investigate the proliferation, differentiation and the meta-
bolic response of subcutaneous adipose-derived stromal cells 
(ADSC) after simulation in vitro of the obesity conditions. 
Human ADSCs have been isolated from subcutaneous adi-
pose tissue of non-obese subjects and maintained in culture 
until the 5th passage. The cells were cultured in the presence of 
sera from obese (oADSC) and non-obese patients (cADSC) 
followed by examination of their proliferation and differen-
tiation into an adipose lineage. After 21 days of differentia-
tion, we evaluated the intracellular lipids accumulation (by 
Oil-Red O staining), the gene expression of the adipogenic 
markers, such as PPAR 2, C/EBP , FABP4, and LPL (by 
-
rescent dye DCFH-DA), the activation of eIF2  and IRE1  
- related metabolic stress pathways, and the expression of 
 West-
ern blotting). The results showed that, compared to cADSC, 
oADSC exhibited: (i) a slower process of differentiation, (ii) 
a hyperplasic phenotype, (iii) accumulation of smaller lipid 
droplets inside the cytoplasm (indicative for altered metabolic 
adaptation), (iv) enhanced expression of adipogenic marker 
genes of PPARg2, C/EBPa, FABP4, and LPL, (v) stimula-
tion of ROS production and enhanced protein expression of 
metabolic stress markers, such as eIF2  and IRE1 , and (vi) 
augmented protein expression of MCP1 and E-selectin. Based 
on the above in vitro results one can infer that exposure of 
stromal cells from subcutaneous adipose tissue to conditions 
similar to those in obesity induced a switch from their basic 
this change may contribute to adipose tissue dysfunction in 
obesity.
is work was funded by the Romanian Academy and 
by the MEN-UEFISCDI through the „Partnership in pri-
ority areas” Programme (PN-II-PT-PCCA-2013-4-2154). 
Alina Constantin acknowledges the !nancial support of 
the European Social Fund within the Sectoral Operational 
Program Human Resources Development 2007-2013 (ID: 
POSDRU/159/1.5/S/133391). 
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DYSFUNCTIONAL HDL IN THE SMALL INTESTINE OF HYPERLIPIDEMIC 
HAMSTERS IS GENERATED BY THE INCREASED ENDOPLASMIC RETICULUM 
STRESS - REVERSE EFFECT OF LOWERING INTESTINAL LIPID TRANSPORT BY 
PROBIOTICS
Camelia S. Stancu1, Mihaela G. Carnuta1, Gabriela M. Sanda1, Laura Toma1, Mariana Deleanu1,2, 
and Anca V. Sima1
1Institute of Cellular Biology and Pathology “Nicolae Simionescu” of the Romanian Academy, Bucharest, 
Romania and 2Faculty of Biotechnology, University of Agronomical Sciences and Veterinary Medicine, 
Bucharest, Romania
Dyslipidemia is one of the causes of obesity, diabetes and ath-
erosclerosis. Decreased HDL-cholesterol is characteristic for 
dyslipidemia. e new hypothesis of “HDL functionality” 
states the relevance of HDL functionality over HDL-choles-
terol for the risk of developing cardiovascular diseases. HDL 
proteins are synthesized in the liver and the small intestine. 
Paraoxonase1 (PON1), the main antioxidant enzyme associ-
ated with HDL, is known to be synthesized in the liver, and 
its decreased activity is connected with HDL dysfunction. 
ere is a debate whether PON1 synthesis takes place in the 
intestine. We aimed to investigate PON1 synthesis in the small 
intestine of hamsters and the mechanisms linking hyperlipid-
emia (HL) with the dysfunctional HDL and the association 
with the aortic valves lesions. We used male Golden Syrian 
hamsters fed either standard chow (N), HL diet (3% choles-
terol and 15% butter) for 20 weeks, or HL diet supplemented 
with probiotics (Lactobacillus acidophilus and Bi!dobacterium 
animalis) (HLP) for the last 4 weeks of the experiment. e 
expression of PON1, apolipoprotein AI (apoAI), lipid trans-
porters (Niemann Pick C1 like 1 - NPC1L1, microsomal tri-
glycerides transfer protein – MTTP), the endoplasmic reticu-
lum stress (ERS) sensors, the transcription regulators, and the 
oxidized lipids were assessed in the small intestine, the liver 
and serum. e lesion areas of the aortic valves were evalu-
ated.  All animals fed the fat diet developed HL, and 50% HL 
and hyperglycemia (HLHG) a!er 16 weeks. PON1 and apoAI 
expression were decreased in the small intestine of HLHG< 
HL< N hamsters. In parallel, ERS was activated, oxidized 
lipids levels and lipid transporters NPC1L1 and MTTP ex-
pression increased, along with the decrease of liver X recep-
tors (LXR) and peroxisome proliferator-activated receptorγ 
(PPARγ). In the liver, the expression of PON1 was reduced, 
the expression of apoAI, ERS sensors and oxidized lipids lev-
els increased, along with the decrease of LXR and PPARγ. 
PON1 protein and activity decreased in HLHG<H<N sera, 
along with the increase of oxidized LDL and the lesion areas 
of the aortic valves (HLHG>HL). e administered probiot-
ics diminished NPC1L1 and MTTP expression, and increased 
PON1, apoAI, LXR and PPARγ expression in the small intes-
tine, in parallel with the decreased lesion areas of the aortic 
valves (HLHG>HL). e HL diet induces the increase of the 
lipid transporters, ERS and oxidative stress, along with the re-
duction of PON1, apoAI, LXR and PPARγ expression in the 
small intestine. e excess oxidized lipids, the reduced PON1 
levels and activity in sera are indicative of the presence of dys-
functional HDL and are accompanied by the development of 
aortic valves lesions. Diminution of the intestinal cholesterol 
uptake a!er probiotics administration restored PON1 expres-
sion and activity, upregulated LXR and PPARγ, and reduced 
the aortic valves lesion areas.
is work was supported by grants from the Romanian 
Academy, National Ministry of Education and Research PNII-




A CORRELATION BETWEEN INTERMEDIARY DIABETES MELLITUS AND OBESITY 
Paul A. Gagniuc1, Constantin Ionescu-Tirgoviste2, Elvira Gagniuc 3, and Cristian Guja2
 1Institute of Genetics, University of Bucharest, Bucharest, Romania, 2National Institute of Diabetes,  
Nutrition and Metabolic Diseases ”N.C. Paulescu”, Bucharest, Romania, and 3University of Agronomic Sciences 
and Veterinary Medicine, Bucharest, Romania
Diabetes mellitus (DM) and obesity have an interwoven rela-
tionship. Type 2 diabetes mellitus (T2DM) is strongly associ-
ated with obesity which stands out as a risk factor. Besides 
obesity, risk factors for T2DM include physical inactivity and 
family history of metabolic disorders and/or atherosclerosis. All 
of the above risk factors should indicate a more narrow range of 
research involving a rened and complex process, namely the 
gene expression patterns. In order to better understand the dia-
betogenic mechanisms, numerous gene expression studies have 
been conducted for unraveling the relationship between these 
heterogeneous phenotypes. However, diabetes studies related to 
the main eectors of gene expression (the promoters of genes) 
were rarely conducted. Here we intend to present the relation-
ship between these eectors in more detail in the context of obe-
sity and diabetes. In our study we used a new method of analysis 
known as „DNA pattern” method, which has been used in the 
past to analyze the structural properties of promoters of genes 
in various species. Among the analyzed promoters of genes as-
sociated with T1DM, we mention the PTPN22, TLR7, CTLA4, 
GSDMB, STAT4, IL7R, C1QTNF6, CD55, CTSH, ERBB3, 
HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-DPB1 and INS 
gene promoters (Fig. A) and for T2D the CAMK1D, DUSP9, 
HHEX, IRS1, MADD, NOTCH2, TP53INP1, VPS13C, WFS1, 
ZFAND6, HMGA2, PPARG, CDKN2AIP, PROX1 and TCF7L2 
gene promoters (Fig. B). In connection with obesity, we con-
sidered the promoters of the following genes: FTO, PCSK1, 
MTCH2, SH2B1, NEGR1, GNPDA2, INSIG2, TMEM18, 
KCTD15, BDNF. e „DNA pattern” methodology allows the 
determination of the coexpression relationships between genes. 
us, the overlapping positions (or close positions) of promot-
ers of these genes inside the distribution indicate that those 
promoters use transcription factors in common. A key goal for 
treatment and prevention of T2DM is the reduction of obesity. 
e main treatment of both conditions is increased physical 
activity and reduced caloric intake. us, by modifying these 
environmental factors, a direct modication of gene expres-
sion patterns is produced. As can be seen in gure below, the 
promoters of genes associated with the two main phenotypes 
(T1DM and T2DM) of diabetes contain dierent DNA pat-
terns, indicating dierent mechanisms of action. However, the 
intermediary diabetes mellitus (IDM) and obesity phenotypes 
show forms of intermediate promoter classes, which makes 
their associated genes functionally receptive to transcription 
factors specic to both T1DM and T2DM phenotypes. Accord-
ingly, the close distribution of promoters of genes associated 
with the analyzed phenotypes depicts a functional correlation 
(co-expression) of these genes. e gure below shows the gen-
eral distribution of the four phenotypes and indicates the pro-
moters of genes positioned at the extremes of the distribution. 
e individual distribution of promoters of genes associated 
with T1DM, T2DM, IDM and obesity it is shown in Figure A 
whereas the global distribution (the mean values) of the four 
phenotypes are shown in Figure B. Our distribution suggests 
that there is a strong correlation between IDM and Obesity (Fig. 
B). e unexpected location of gene promoters associated with 
obesity, closer to T1DM (Fig. B), could indicate the immune 
response known as low grade in!ammation commonly associ-
ated with obesity. In our study we used the promoters of genes 
associated with T1DM, T2DM, IDM and obesity. Our analysis 
showed that IDM and obesity genes are equipped with promot-
ers prone to common triggers. Also, IDM and obesity associat-
ed genes (with promoters similar in structure) are functionally 
receptive to transcription factors specic to both T1DM and 
T2DM phenotypes.
is work was supported by CERO, grant number 
POSDRU/159/1.5/S/135760.
